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ABSTRACT 
NICOLE FOUCHÉ: Structural Analysis of Telomere Binding Factors and 
Repetitive DNAs 
(Under the direction of Jack D. Griffith)  
 
Telomeres are typically long nucleoprotein structures that protect the ends of 
linear chromosomes from exonucleolytic attack and from being recognized as 
DNA double strand breaks.  Telomeric DNA is lost either gradually, as a 
consequence of cellular ageing, or sometimes rapidly, when the telomere 
structure is disrupted or due to errors in telomere maintenance.  When greatly 
shortened, telomeres will signal a DNA damage message that results in an 
active growth arrest and eventually, cell death.  Telomeres are thus molecular 
clocks that present a formidable barrier against cancer, because functional 
telomeres are essential for continued cell proliferation.  Thus an important 
strategy for cancer therapeutics lies in understanding and targeting telomere-
lengthening mechanisms used by cancer cells.   However, telomere length is 
determined by the intricate interplay of the components that lengthen 
telomeres and those that shorten them.  Therefore, a detailed understanding 
is also needed of the structures and functions of telomere factors present in 
normal cells, and of how changes in these can lead to cancer.  Presented 
here are structural analyses of the telomeric DNA itself; the yeast RNA 
component of the telomere-lengthening protein, telomerase; and the DNA 
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binding properties of telomerase and another telomere-specific protein, TRF2.  
Together, the data adds to a more comprehensive structural model for the 
manner in which telomeres function in vivo. 
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CHAPTER 1: INTRODUCTION 
 
Telomeres are protein-DNA structures that regulate the action of 
cellular proteins at the ends of linear chromosomes.  They consist of long 
arrays of repeated DNA elements, bound by specific DNA binding proteins, 
and which terminate in a single-stranded (ss) 3’ overhang (1,2).  In all 
vertebrates, telomeric DNA is comprised of the tandem repeat TTAGGGn 
(3,4).  In humans, this non-coding DNA extends from 5 to 15 kilobase pairs, 
depending on the tissue and donor age, ending in an overhang that ranges 
from ~60 to 200 nucleotides in length (5-9).  Telomeric chromatin is thought to 
be organized into lariat-like structures (t-loops) found at the ends of the 
telomeres of humans, mice, plants, yeasts and protozoa (10-15).  Human 
telomeric DNA in vivo is complexed by the components of the shelterin 
complex, which are unique to the telomere and include the ds DNA telomere 
repeat binding factors 1 and 2 (TRF1 and TRF2), the ssDNA telomere factor 
Protection of Telomeres 1 (POT1), and the proteins that bind to them, Rap1, 
Tin2 and Tpp1 (16-18).  A host of other cellular proteins are found at the 
telomere, including DNA-repair factors such as Ku70/80 and the Mre11-
Rad50-NBS1 complex required for the S-phase DNA damage checkpoint, the 
homologous recombination (HR) protein RAD51D and the histones (19-21). 
 2 
TELOMERE LENGTH MAINTENANCE 
Most eukaryotic telomeres shorten by ~50-200 nt during each cell 
cycle, due to the ‘end-replication problem’, oxidative damage, and nucleolytic 
processing (7,22-28).  In cells with indefinite replicative potential, leading 
strand telomeric repeats can be restored by the reverse transcriptase 
telomerase, while the lagging strand is concurrently elongated by the 
standard replicative machinery (29,30).  However, the activity of telomerase is 
negligible in human somatic cells and in culture these cells will cease to divide 
when their telomere length decreases to ~3 kb (31).  This arrested state has 
been termed replicative senescence, or mortality stage 1 (M1), and is further 
characterized by an enlarged cell size, expression of a pH-dependent β-
galactosidase activity and an altered pattern of gene and protein expression 
(32).  In the absence of p53 and/or p16/Rb, cells can bypass M1 senescence 
and continue to divide.  Thus, telomeres continue to shorten and this will 
usually result in mortality stage 2 (M2) characterized by many ‘uncapped’ 
chromosome ends, mitotic catastrophe and a high fraction of apoptotic cells 
(33).  
Evidence for the direct involvement of telomere length in replicative 
senescence, is that this process can be prevented by the expression of 
hTERT, the catalytic component of the ribonucleoprotein telomerase (34-36).  
Normal human cells stably expressing transfected telomerase either before 
M1 or in between M1 and M2 can divide indefinitely.   Telomeres are thus a 
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potent tumor-suppressor mechanism in the cell, acting as molecular clocks 
that count the number of times a cell has divided. 
Telomerase 
The telomerase complex consists of a telomere-specific reverse 
transcriptase protein, a template RNA and accessory factors (37-39).  The 
protein subunit (TERT in humans and ciliates and EST2 in yeast) is able to 
maintain telomere length by using the 3′ single-strand overhang as a primer 
and a defined region of its integral RNA component (hTERC in humans and 
TLC1 in yeast) as a template for the de novo synthesis of telomeric repeats 
(40-43).  The exact mechanism used is not yet understood, but we present 
evidence in chapter 2 that supports a model in which two cooperating 
telomerase enzymes that bind to and extend a single DNA substrate.  Also, 
we present evidence in chapter 3 that is consistent with a model for an 
additional function of the RNA component, that is, to act as a flexible scaffold 
for the telomerase protein subunits (44,45).   
In telomerase-positive human cells, telomere length is partly controlled 
by a feedback mechanism in which telomere elongation by telomerase is 
limited by the accumulation of the TRF1 complex at chromosome ends 
(reviewed in (46).  More specifically, the amount of TRF1 present at telomeres 
is dependent on their lengths, the TRF1 complex interacts with and regulates 
POT1 binding, and human POT1 controls telomerase access to telomeres 
(47-49).  In vitro EM studies have shown that TRF1 binds to the ds 
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telomeric tract in long filamentous arrays, and in the presence of TRF1, 
loosely-formed telomeric chromatin becomes tightly compacted (Nicole 
Fouché, unpublished data).  Also, TRF1 specifically recognizes nucleosomal 
binding sites and alters nucleosome structure (50).  These data suggest that 
TRF1 may be involved in the formation of a complex folded structure at the 
telomere that restricts telomerase access to the overhang within the larger 
context of telomeric chromatin. Perhaps it is this structure that requires a 
minimum of ~3 kb of telomeric DNA in humans, below which the resultant 
change in telomere state (uncapping) leads to growth arrest.  
Alternative lengthening of telomeres 
In the absence of telomerase, chromosome ends can also be 
maintained by recombination (51-53).  Between 5 and 10% of human cancers 
maintain their telomeres via a telomerase-independent recombination 
pathway called alternate lengthening of telomeres (ALT) (54).  Interestingly, 
mammalian ALT cells often contain some very long telomeres up to ~50 kb.  
Because ALT is a cancer-associated phenotype, it arises during escape from 
crisis when most telomeres are very short.  Thus it is perplexing that these 
cells are able to use recombination to generate longer telomeric repeats.  A 
possible solution to this problem has been proposed, in which rolling circle 
replication of telomeric repeat-containing circles is combined with the 
standard mechanisms of sister chromatid exchange (55-57).  Specifically, the 
ALT mechanism is thought to involve loss of a repressor that controls 
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inappropriate HR at the telomere, resulting in a resolution event at the t-loop 
junction (t-loop HR) and the formation of t-loop sized telomeric circles (t-
circles).  Consistent with this idea, ALT cells contain abundant telomeric 
circles that are generated as a result of recombination events, because 
knockdown of XRCC3 or NBS1, two proteins associated with t-loop HR, 
abolished these circles in ALT cells (S. Compton unpublished data and 
(58,59). 
 
STRAND-SPECIFIC TELOMERE PROTECTION 
Telomere “end-capping” serves to hide the chromosome ends from 
factors in the cell that would otherwise process them as double-strand breaks 
or HR intermediates.  Telomere protection involves multiple pathways, 
including repression of non-homologous end joining (NHEJ), repression of a 
DNA damage signal, protection from inappropriate HR, and control of 
telomere end processing after replication.  When telomeres become 
“uncapped” due to a change in the telomeric DNA structure or sequence, or 
when telomere proteins are depleted or mutated, a rapid induction of growth 
arrest ensues.  This growth arrest, termed STASIS (STress or Aberrant 
Signaling Induced Senescence) is similar to replicative senescence, but it is 
thought to be brought about by a different signaling pathway (60,61). 
Control of telomere end processing after replication 
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Upon the completion of replication in telomerase-negative cells, leading-
strand telomere ends are blunt, because DNA synthesis is continuous on this 
strand.  Conversely, lagging-strand telomeres have a 3′ overhang, owing to 
removal of the last RNA primer plus the possible failure of the last priming 
event (end replication problem, Figure 1.1 A-B, (22,23).  Because overhangs 
are present on both chromosome ends however, it is presumed that a 
nuclease acts on the 5′ C strands of at least the leading-strand telomeres 
(28).  The 5′ to 3′ nuclease Artemis may be this C strand nuclease, because 
Artemis deficiency results in increased telomere end-to-end fusions, a 
hallmark of missing overhangs (62). 
Interestingly, the terminal nucleotides at C strands are the same on 
both leading and lagging daughter telomeres, ending at 5′-ATC (28).  This 
suggests that a similar mechanism acts to resect the C strands of both the 
lagging and leading daughter telomeres.  This mechanism of C strand 
resection is likely conserved, because Euplotes and Tetrahymena also 
possess precise nucleotide sequences at C-strand termini (28,63-65). 
Recently, the shelterin component Protection of Telomeres 1 (POT1) 
was found to dictate the precise sequence of the 5′ C strand terminus (62).  
Thus, POT1 is thought to constrain the action of the nuclease involved, 
providing the nucleotide-specific boundary for 5′ to 3′ exonuclease trimming.  
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Figure 1.1: Model of strand-specific telomere protection. 
Schematic of the processes involved in telomere end-capping following 
replication.  (A). Strands containing TTAGGG repeats are depicted in grey; 
strands containing AATCCC repeats are depicted in black.  Nascent leading 
strand indicated by solid grey arrow, nascent lagging strand indicated by 
broken black arrows.  Replication machinery and shelterin components 
omitted.  (B - C). Lagging strand replication generates a natural 3′ overhang 
(top strand) whereas leading strands are blunt-ended after telomere 
replication has completed (bottom strand).  In this case, overhang generation 
seems to require nuclease activity.  (D). T-loops on lagging (top) and leading 
(bottom) daughters may have different structures at the sites of strand-
invasion, and they may be stabilized by different proteins.  
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Indeed, the absence of POT1 at telomeres results in 3′ overhang elongation 
(66-68). 
Repression of NHEJ 
Telomere overhangs are presumably required for telomere end capping via t-
loop formation (10).  The crucial feature of t-loops is thought to be the 
invasion of the 3’ ss overhang into the duplex repeat tract (Figure 1.1 D).  
Consistent with this idea, POT1, which binds directly to the G-strand 
overhang, is not required to protect the overhang from degradation and has a 
relatively minor role in preventing telomere fusions (66-68).  On the other 
hand, loss of TRF2, which can remodel linear telomeric DNA into t-loops in 
vitro, leads to a dramatic telomere-fusion phenotype (69-71).  The fusions 
arise because the nucleotide excision repair nuclease ERCC1/XPF removes 
the G-overhangs from the uncapped telomeres, allowing ligation of the 
chromosome ends by the NHEJ machinery (72,73).  Thus, TRF2 but not 
POT1, is required for overhang protection and repressing NHEJ, presumably 
by facilitating t-loop formation at the chromosome ends. 
Protection from inappropriate HR 
The exact structure of the strand invasion site of the t-loop is not 
known.  A widely proposed model suggests limited strand invasion of just the 
G-rich strand, to form a displacement loop  (D-loop) (Figure 1.1 D, lagging 
strand (10).  EM studies incorporating E. coli single-stranded binding protein 
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(SSB) staining of ssDNA at the t-loop junctions indicated the presence of 75 
to 200 nt of ssDNA.  This suggests that overhangs of a similar length had 
inserted into the duplex repeat tract, resulting in a stretch of displaced G 
strand DNA that could be coated by the SSB. 
Another proposed model for the strand invasion structure involves 
branch migration of the D-loop and more extensive strand invasion involving 
both the G and C strands, resulting in a Holliday junction resembling a DNA 
recombination intermediate (Figure 1.1 D, leading strand, (69).  Consistent 
with this idea, EM studies using a linear model telomere with a very short (6 
nt) TTAGGG-3′ tail generated a t-loop that was covalently fixed with psoralen 
and UV.  Thus, it seems probable that in the case of a short overhang, this 
four-stranded structure is more stable, and thus more energetically favorable, 
than the D-loop. 
Evidence suggests that the structures at the ends of leading- versus 
lagging-strand telomeres may be different (see model in Figure 1.1 D).  In 
normal cells, leading strand overhangs are significantly shorter than lagging 
strand overhangs (60 nt versus 105 nt, (5).  Also, overexpression of a mutant 
TRF2 protein (TRF2∆B) results in preferential deletion of leading strand t-loops 
by HR, resulting in telomere shortening, a DNA damage response, t-circles 
and induction of senescence (59).  In chapter 5 we will show that this mutant 
of TRF2 has lost the ability to bind to DNA junctions, specifically four-stranded 
junctions, even though it retains DNA binding activity (59).  On the other 
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hand, loss of the murine POT1 paralog (POT1a) results in preferential loss of 
lagging strand telomeres, a DNA damage response, t-circles, and aberrant 
HR at telomeres (66,67).  Furthermore, leading daughter overhangs are 
preferentially extended in telomerase expressing cells (5).  Because POT1 
negatively regulates telomere extension by telomerase, it is possible that 
POT1 restricts telomerase access to the overhangs at lagging strand t-loops, 
but not leading strand t-loops (48,74).  Thus, it seems plausible that the 
structure at the base of the t-loop in the leading strand may be the more 
energetically favored four-stranded Holliday junction, stabilized by TRF2, 
whereas lagging strand overhangs may be sufficiently long for stable D-loop 
formation, stabilized by POT1 binding to the displaced ssDNA.   
Interestingly, it appears that the ds telomeric DNA binding activity of 
the TRF2 Myb domain alone, presumably in the context of a shelterin 
complex, is necessary for t-loop formation.  Whereas the basic domain was 
required for t-loop formation in vitro (discussed in Chapter 5), it is dispensable 
for t-loop formation in vivo, as evidenced by the presence of t-circles and the 
lack of NHEJ in cells expressing TRF2∆B (59).  T-circles are also seen in 
mouse knockouts of POT1, suggesting that although this protein may be 
needed for stabilizing the (lagging strand) D-loop, it is not necessary for t-loop 
formation.  Conversely, t-circles are absent after conditional deletion of the 
TRF2 gene in mouse embryo fibroblasts or upon expression of the dominant-
negative mutant that removes endogenous TRF2 from telomeres (TRF2∆B∆M) 
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even when the NHEJ pathway is inactive (59,70,71,73,75).  
Repression of a DNA damage signal 
It appears that in addition to t-loop formation, other factors are required 
to suppress the DNA damage signal.  In the above-mentioned POT1 deletion 
and TRF2∆B phenotypes, a DNA damage response was detected despite the 
presence of t-loops (59,62,66,67).  In addition, an apoptotic signal is 
generated after TRF2 inhibition, even without concomitant overhang 
degradation, telomere replication or chromosome segregation (73,76).  
Indeed, subunits of the Mre11 complex (a DNA damage sensor of the ATM 
pathway) are present at human telomeres throughout the cell cycle (20,77-
79).  This suggests that the potential for damage recognition is ever-present 
at the telomere. 
One solution to this problem may lie in the ability of TRF2 to bind to the 
Ataxia-telangiectasia mutated (ATM) kinase and inhibit the ATM-dependent 
DNA damage response (80).   This would be especially important during 
replication and prior to t-loop formation, when the telomere is unfolded and 
the overhang is exposed.  Indeed, ATM is recruited to telomeres in late S or 
G2 phase, where it initiates a transient DNA damage response that is 
subsequently quenched, presumably by refolding of the telomere by the 
shelterin complex (81-84). However, in the absence of ATM, TRF2 inhibition 
still results in Telomere Dysfunction-Induced Foci (TIFs) and senescence, 
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pointing to a second ATM-independent damage-signaling pathway (81). 
In human cells, ssDNA alone is able to promote checkpoint activation, 
by recruiting replication protein A (RPA), which in turn recruits the ataxia-
telangiectasia Rad3-related protein kinase (ATR), a key player in the cellular 
response to DNA damage (85-87).  RPA is present at the telomeres of the 
yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe, and it 
is directly involved in telomere maintenance (88-90).  RPA is also associated 
with the telomere maintenance phenotype Alternative Lengthening of 
Telomeres (ALT) in some human cancers (91,92).   Thus it may be that, at a 
minimum, preventing inappropriate binding of ssDNA binding proteins (e.g. 
RPA) to ssDNA at the telomere (e.g., at the D-loop), is needed to suppress 
the telomere-induced DNA damage signal.  This role may be attributed to the 
ss telomeric DNA binding protein, POT1, as was previously suggested, as this 
would be consistent with the loss of POT1 leading to a telomeric DNA 
damage response without disruption of the core telomere protein complex or 
telomere uncapping (68). 
 
STRAND-SPECIFIC TELOMERE LOSS 
The mechanism underlying stochastic telomere loss is not known, but 
may be a result of deletion of t-loops by homologous recombination, or the 
failure to unwind or correctly process higher-order structures of G-rich 
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telomeric DNA during telomere replication (59,66,93,94).  However, the 
conventional models do not explain the strand-specific phenotypes that arise 
from telomere replication.  We have discussed the idea of strand-specific 
deletion of t-loops by HR that could result from differential t-loop formation 
during postreplicative “recapping” of the leading and lagging strands (above).  
Taking into account the data presented in chapters 4 and 5, we now propose 
an additional model for replication-coupled telomere shortening that would 
also account for these strand-specific telomere deletions. 
Problems associated with telomere replication 
The telomere is thought to be replicated by the conventional semi-
conservative polymerase machinery, including polymerases α and δ 
(30,63,95).  However, the repetitive nature of the telomeric DNA likely 
presents inherent difficulties for the DNA synthesis machinery.  In addition to 
the presence of G-quartets or tetrameric structures known to form on both the 
leading and lagging strands, telomeres are thought to accumulate oxidative 
DNA damage as a result of their high triple-G content (25,96-98).  Another 
impediment to the moving replication fork is the t-loop that must be unfolded 
for the replication machinery to reach the very end of the telomere, as well as 
the proteins that are needed to protect the ends from DNA repair factors 
during this time.  Furthermore, in chapter 4, we present data that suggests 
that stalled replication forks at telomeric repeats have a higher propensity to 
regress, forming stable four-stranded chickenfoot structures (resembling 
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Holliday junctions) that would also need to be resolved before replication 
could continue (Figure 1.2 B).  
Telomere-specific replication factors 
It is possible then that telomere-specific factors facilitate replication of 
the telomere (99).  Telomeres are replicated as rapidly as the bulk DNA, and 
recently, the telomere binding protein in S. pombe (Taz1) was determined to 
be necessary for efficient replication of yeast telomeres (100,101).  Also, 
Bloom’s (BLM) and Werner’s (WRN) syndrome helicases, have been shown 
to be important for proper telomere replication and maintenance in human 
cells (94,102-106).  These RecQ helicases have been shown to unwind G 
quartets and D-loop structures, and to promote branch migration of 4-
stranded junctions similar to chickenfoot structures in telomeric DNA 
templates (107-114).  Moreover, the requirement for telomere-specific 
helicase activity appears to be conserved, because at least four different 
helicases have been reported to be involved in telomere function in S. 
cerevisiae, and the putative DNA helicase, Rtel, is a putative regulator of 
telomere length in mice (93,115-117). 
Replication restart 
Although factors at the telomere are able to facilitate unwinding of G 
quartets and even the D-loop, the replication fork is still expected to stall or 
collapse at sites of DNA damage known to be present at the telomere    
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Figure 1.2: Model of strand-specific replication restart 
Schematic of the potential problems encountered during telomere replication 
and replication restart that could lead to preferential deletion of daughter 
strands.  (A). Stalled replication due to a problem such as a site of DNA 
damage (star) or a G-quartet (quadruplex symbol).  Strands containing 
TTAGGG repeats are depicted in grey; strands containing AATCCC repeats 
are depicted in black.  Nascent leading strand indicated by solid grey arrow, 
nascent lagging strand indicated by broken black arrows. (Replication 
machinery omitted).  (B). Chickenfoot structure and the proteins that may 
control replication fork regression versus unwinding of problematic structures 
(i.e. G-quartets).  Black arrows indicate sites of G strand cleavage.  (C). G 
strand cleavage by Holliday junction resolvases would lead to a double strand 
break on the lagging strand telomere.  Subsequent exonuclease activity may 
be required to generate a 3′ overhang for replication restart.  (D). Replication 
restart may require the activities of WRN and POT1 for D-loop formation.  (E). 
Strand migration or lagging strand elongation of the complementary strand of 
the D-loop are required to form another Holliday junction structure.  Black 
arrows again indicate sites of G strand cleavage by Holliday junction 
resolvases.  (F). The replication fork is re-established.  (A2 - B2). Alternate 
cleavage (black arrows) of the C strands of the chickenfoot structure and then 
subsequent failure of the replication fork to restart would lead to the loss of 
leading strand telomeres. 
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(25,26,118).  Nevertheless, replication forks are endowed with an 
extraordinary potential to coordinate fork stalling with fork resumption 
processes.  Stalled forks generate single-stranded DNA that activates the 
replication checkpoint, which in turn functions to protect the stability of the fork 
until replication can resume (118).  In the absence of converging forks at the 
telomere, however, recombination-mediated replication restart and/or 
damage-bypass mechanisms are expected to facilitate completion of 
replication, because they do not require replication initiation functions 
(118,119). 
The first step in recombination-mediated replication restart involves 
fork reversal to form a four-stranded chickenfoot intermediate (Figure 1.2 B).  
In chapter 5, we will present data that shows that TRF2 recognizes and binds 
with high affinity to these structures in vitro, suggesting that they do in fact 
occur at telomeres in vivo.  Indeed, because repetitive DNA has a natural 
tendency to form chickenfoot structures, it seems plausible that telomere 
replication would have evolved in order to take advantage of this trait, 
selecting for replication restart via homologous recombination over a damage-
bypass mechanism.   
Consistent with this idea, the HR protein RAD51D associates with 
telomeres and is required for proper telomere maintenance in mouse 
embryonic fibroblasts (120).  This Rad51 paralog forms a complex with 
RAD51B, RAD51C and XRCC2 (BCDX2) that is able to promote 
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formation of chickenfoot structures on synthetic replication forks, and which 
can bind to and facilitate cleavage of Holliday junctions in vitro (S. Compton, 
unpublished data and (121).  In mammalian cells, RAD51C is required both 
for branch migration and HJ resolution (122). Observations in yeast have also 
suggested an active Rad51-dependent process of four-way junction formation 
at stalled forks deprived of the replisome (123).  It is possible, then, that 
TRF2-shelterin, in complex with some Rad51 paralogs, associates with 
stalled fork intermediates to direct fork regression and subsequent cleavage 
of the G strands by Holliday junction resolvases  (black arrows, Figure 1.2 B, 
chapter 5).   
This would effectively release the lagging strand telomere as a free 
end (Figure 1.2 C).  As previously discussed, the Mre11 complex is 
associated with human telomeres (20). However, the regulatory subunit of 
Mre11, Nbs1, joins TRF2 at telomeres only in S phase, suggesting a role for 
this complex in telomere replication (20).  Mre11 is capable of tethering DNA 
fragments, such as the free end of the lagging strand telomere, and it was 
recently suggested that the essential role of the Mre11 complex in vertebrates 
might be attributed to the restart of collapsed replication forks (124-127).  
Interestingly, the association of ATM with TRF2, which did not block ATM 
kinase activity in vitro, would further stimulate this activity of Mre11, because 
ATM and ATR are able to promote Mre11-dependent restart of collapsed 
replication forks (80,127).  ATM-like kinases are also necessary for telomere 
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maintenance in S. cerevisiae (128) and S. pombe (129). 
The next steps in recombination-mediated replication restart would 
presumably involve strand resection of the lagging C strand 5′ terminus 
(Figure 1.2 C), strand invasion of the resultant 3′ G overhang into the leading 
strand duplex repeats (Figure 1.2 D) and strand migration or lagging strand 
elongation of the complementary strand of the D-loop, to form a Holliday 
junction structure (Figure 1.2 E).  The final step would be relatively identical to 
the first, involving Holliday junction resolution by an activity that again cleaves 
the G strands (black arrows, Figure 1.2 E).  Evidence for this mechanism of 
replication restart along tracts of repetitive DNA has come from studies of 
long tracts of CTG repeats, associated with myotonic dystrophy, that undergo 
deletion at a high rate in plasmids in Escherichia coli (130,131).   
Because the above-mentioned steps resemble t-loop formation and t-
loop HR, these processes would no doubt require the actions of several 
proteins already implicated in telomere end capping or t-loop HR.  Thus the 5’ 
C strand exonuclease would likely be the same protein involved in C strand 
resection during telomere end processing and would likely be regulated by 
POT1 binding to the overhang (Figure 1.2 C).  Strand invasion during HR is 
typically catalyzed by the combined actions of RAD51, RAD52 and RPA, of 
which RAD51 and RPA both have telomere phenotypes (88-90,120,132).  
However, WRN also naturally co-localizes with RPA upon replication arrest 
and is able to prevent aberrant recombination events at sites of 
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stalled replication (108).  Since POT1 cooperates with WRN to efficiently 
unwind telomeric substrates in vitro, both proteins may also be required for 
formation of the strand-invasion D-loop structure at telomeres (Figure 1.2 D 
and (133).  POT1 may also be required to stabilize the D-loop structure by 
binding to the displaced ss G rich DNA (Figure 1.2 D).  Moreover, WRN may 
be required for branch migration of the D-loop or lagging strand synthesis 
required to establish a bona fide recombination substrate between the two 
replicating strands (Figure 1.2 E).  Consistent with this idea, deletion of POT1 
in mice leads to the preferential loss of lagging strand telomeres, and human 
cells lacking WRN also exhibit deletion of telomeres replicated by lagging 
strand synthesis (66,94).  Because telomeric G- and C strand synthesis are 
coordinately regulated in Euplotes crassus, this suggests that in eukaryotes, 
leading strand replication is unlikely to continue in the absence of lagging 
strand replication (63).  Thus, a possible explanation for the above-mentioned 
phenotypes could be that collapsed replication forks that had already been 
cleaved as in Figure 1.2 C, failed to restart in these cells.  Indeed, if this 
occurred close to the sites of replication initiation, the lagging strand 
telomeres would have been effectively removed.  In this case, lack of 
replication of the lagging strand telomeres is expected to mimic telomere loss.   
At telomeres, the key regulatory factor involved in replication appears, 
however, to be TRF2.  In human cells, TRF2 co-localizes and physically 
interacts with WRN (134), and it binds to and stimulates the activities of both 
the WRN and BLM helicases in vitro (105).  Also, the dominant negative 
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mutant of TRF2 (TRF2∆B∆M) is able to bind to POT1 and prevent it from 
localizing to telomeres, suggesting that TRF2 binding to telomeric DNA may 
be required for POT1 recruitment to, for example, recombination 
intermediates with little to no ssDNA present (Figure 1.2 C, (135).  However, it 
is the separation of function mutant of TRF2 (TRF2∆B) that may have revealed 
the most about TRF2 function during telomere replication.  When TRF2∆B was 
expressed in cells, it induced catastrophic deletions of telomeric DNA in which 
both the C-rich and the G-rich strands became shortened (59).  However, as 
previously mentioned, TRF2∆B expression resulted in the preferential deletion 
of leading strand telomeres, suggesting problems during telomere replication 
(59).  This was dependent on XRCC3 (another Rad51 paralog associated 
with Holliday junction resolution activity) and Nbs1, suggesting problems 
during replication restart via the recombination pathway.   
Although TRF2∆B is unable to bind to the chickenfoot intermediates of 
fork regression, it is still able to bind to the duplex telomeric repeats and 
thereby recruit the proteins, such as POT1 and WRN that may be needed for 
efficient replication.  Thus, the loss of leading strand telomeres may be limited 
to problems encountered during telomere end-capping, as previously 
discussed.  However, another possible explanation exists if we consider a 
possible novel function for TRF2 at stalled replication forks.  That is, if TRF2 
was needed to direct the preferential cleavage of the G rich strands of 
chickenfoot intermediates, then this could also account for the postreplicative 
loss of leading strand telomeres in the TRF2∆B phenotype (Figure 1.2 A2, 
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B2).  Evidence suggests that the C rich strands may indeed be the default 
during Holliday junction resolution.  In humans, the branch migration-
associated resolvase (of which RAD51C and XRCC3 are components) 
cleaves Holliday junctions preferentially between two cytosine residues 
(122,136). 
 
SCOPE OF DISSERTATION 
Presented here are structural analyses of three of the key components 
of the telomere: telomeric DNA, telomerase and TRF2.  The primary goal was 
to reveal mechanistic clues that would contribute to the broader 
understanding of the way in which telomeres regulate, and are regulated by, 
processes in the cell. 
In Chapter 2, we present data obtained in collaboration with the 
laboratory of Michael B. Jarstfer, that was published in the journal 
Biochemistry, and which is reproduced here with permission (137).  The 
binding of the telomerase ribonucleoprotein from the ciliate Euplotes 
aediculatus to telomeric DNA in vitro is examined by electron microscopy 
(EM).  Visualization of the structures that formed revealed a globular protein 
complex that localized to the DNA end containing the E. aediculatus telomere 
consensus 3'-single-strand T4G4T4G4T4G2 overhang.  Gel filtration confirmed 
that purified E. aediculatus telomerase is an active dimer in solution, and 
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comparison of the size of the DNA-associated complex with apoferritin 
suggests that it binds to a single telomeric 3'-end as a dimer.  Up to 43% of 
the telomerase-DNA complexes appeared by EM to involve tetramers or 
larger multimers of telomerase in association with two or more DNA ends.  
These data provide the first direct evidence that telomerase is a functional 
dimer and suggest that two telomerase ribonucleoprotein particles cooperate 
to elongate each Euplotes telomere in vivo. 
Recently, a detailed working model for the secondary structure of the 
S. cerevisiae telomerase RNA, TLC1, was proposed by the laboratory of 
Thomas R. Cech, using mfold predictions of energetically favorable RNA 
conformations coupled with genetic, biochemical and phylogenetic data from 
four species of Saccharomyces (44). This model proposes that the 
telomerase RNA consists of a central catalytic core containing the RNA 
template and Est2p-binding region, plus three long quasihelical RNA arms 
that bind to telomerase accessory factors.  In chapter 3 we have used EM, in 
collaboration with the Cech laboratory, to test this mfold structure prediction.  
We directly visualized a full-length TLC1 RNA, as well as a deletion mutant 
(∆∆) proposed to have truncation of the longest RNA helix.  Our results were 
consistent with the existence of three RNA arms in the full-length molecule.  
Also, a nano-scale ‘biopointer’ confirmed that in the majority of molecules, a 
biotinylated oligonucleotide that was complementary to the RNA template 
region was most often located at the center of the RNA. 
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Chapter 4 describes a study examining two of the repetitive sequences 
found in the human genome: the telomeric repeat, necessary for the 
protection of chromosome termini, and the disease-associated triplet repeat 
(CTG)•(CAG)n.  Evidence suggests that replication of both types of repeats is 
problematic, and that a contributing factor is the repetitive nature of the DNA 
itself.  Here we have used EM to investigate DNA structures formed at 
replication forks on large model DNAs containing these repeat sequences, in 
an attempt to elucidate the contributory effect that these repetitive DNAs may 
have on their replication.  Visualization of the DNA revealed that there is a 
high propensity for a paused replication fork to spontaneously regress when 
moving through repetitive DNAs, and that this results in a four-way 
chickenfoot intermediate that could present a significant block to replication in 
vivo, possibly leading to unwanted recombination events, amplifications or 
deletions. 
The replication of long tracts of telomeric repeats may therefore require 
specific factors to avoid fork regression. In Chapter 5 we show that TRF2 
binds to model replication forks and 4-way junctions in vitro, in a structure-
specific, but sequence-independent manner.  A synthetic peptide 
encompassing the TRF2 basic domain also binds strongly to DNA 4-way 
junctions, whereas the TRF2 truncation mutant (TRF2∆B) and a mutant basic 
domain peptide do not.  In the absence of the basic domain, the ability of 
TRF2 to localize to model telomere ends and facilitate t-loop formation in vitro 
is greatly diminished.  We propose that TRF2 plays a key role during 
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telomere replication in binding chickenfoot intermediates of telomere 
replication fork regression.  Junction-specific binding would also allow TRF2 
to contribute to the stability of a three- or four-stranded DNA structure that 
may exist at the strand invasion site of the t-loop. 
CHAPTER 2: ELECTRON MICROSCOPIC VISUALIZATION OF 
TELOMERASE FROM EUPLOTES AEDICULATES BOUND TO A MODEL 
TELOMERE DNA1 
 
INTRODUCTION 
Telomeres are nucleoprotein structures essential for chromosome 
stability in eukaryotes and regulation of the replicative lifespan of somatic 
cells.  Encompassing the termini of all linear chromosomes, the telomeric 
DNA typically consists of long arrays of short tandem repeats (4) bound by 
specific DNA binding proteins, and terminates in a single-stranded 3′ 
overhang (1,2).  In the absence of telomerase or another mechanism to 
maintain telomere length, most eukaryotic telomeres shorten by 50-200 
nucleotides (nt) during each cell cycle, due in part to the ‘end replication 
problem’ that results from the inability of the lagging strand to be replicated to 
the very end of the chromosome (22,23).   
                                            
1 This chapter was published in Fouché N. et al. (2006) Biochemistry 45 (31), 9624-31. 
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The telomere-specific reverse transcriptase telomerase is able to maintain 
telomere length by using the single strand overhang as a primer and a 
defined region of its integral RNA component as the template for the de novo 
synthesis of telomeric repeats (37,138).  One unique feature of telomerase is 
its ability to add multiple copies of the repeat to a DNA substrate following a 
single initial binding event (138,139).  This telomerase processivity depends 
on two types of translocation, type I or nucleotide addition processivity and 
type II or repeat addition processivity (140,141).  Nucleotide addition 
processivity involves simultaneous movement of the RNA–DNA duplex 
relative to the active site after each nucleotide addition.  Repeat addition 
processivity involves unpairing of the RNA–DNA hybrid after repeat addition, 
followed by translocation and re-alignment of the DNA substrate relative to 
the 3' region of the RNA template.  It has been proposed that telomerase can 
also associate with its DNA substrate via template-independent interactions 
that are regulated by a protein-dependent anchor site (142) and that these 
interactions may determine whether the product can remain bound to 
telomerase when released from the template site (143). 
A feature of telomerase that may contribute to telomerase processivity 
is its ability to form dimers or multimers.  Human TERT, the reverse 
transcriptase component of telomerase, as well as telomerase RNA form 
functionally cooperative oligomers in cell lysate or when reconstituted in vitro 
(144,145) and a mutation that weakens human telomerase RNA dimerization 
preferentially impairs type II processivity (146).  Tetrahymena 
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thermophila telomerase eluted from a gel filtration column at the size of a 
monomeric complex (147), but in Saccharomyces cerevisiae the telomerase 
ribonucleoprotein particle (RNP) contains at least two active sites that both 
act as templates for DNA polymerization (148).  Also, while glycerol gradient 
centrifugation of purified Euplotes aediculatus telomerase suggested an 
active RNP monomer in solution (149), gel filtration chromatography of E. 
aediculatus nuclear extracts revealed a functional telomerase complex in 
agreement with telomerase dimer formation (150).  Indeed, Euplotes crassus 
telomerase complexes contain at least two active sites and the telomerase 
catalytic subunit EcTERT undergoes multimerization in vitro (151). 
The existence of telomerase multimers suggests that two or more 
telomerase RNP’s may cooperate during processive elongation to 
simultaneously extend one or more DNA substrates. Three models have thus 
been proposed for such cooperation in a coordinated dimer (145,148,152).  
The parallel extension model consists of two active sites within two different 
but associated telomerase RNP’s simultaneously extending two separate 
chromosome 3′ ends (145,148).  It has been proposed that this type of 
coordinated extension could exist for elongation of both leading and lagging 
strand telomeres after DNA replication of sister chromatids.  The template 
switching model evokes two catalytic sites within a dimer of telomerase acting 
sequentially during processive telomere synthesis to elongate a single 
telomere 3′ end (145).  After addition of a repeat by the first telomerase RNP 
and upon translocation, the DNA substrate is re-aligned relative to 
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the 3′ region of the RNA template within the second telomerase RNP.  The 
DNA anchor site model proposes one telomerase RNP template stabilizing 
the interaction with a single telomere, while the other template is used for 
reverse transcription of the 3′ end (152).  The template of one telomerase 
subunit is thus used primarily for substrate binding, presumably interacting 
with nucleotides upstream of the 3′ end of the DNA substrate, while the other 
is copied during telomere repeat addition.  It is possible that these models are 
not mutually exclusive, but that combinations of all three may exist, with the 
exact mechanics yet to be revealed. 
E. aediculatus is a hypotrichous ciliate with a polyploid macronucleus 
containing millions of gene sized chromosomes (153).  The abundance of 
telomerase in each E. aediculatus cell thus makes it possible to routinely 
purify telomerase from crude extracts.  E. aediculatus telomerase contains 
three subunits including EaTR, the 64 kDa RNA subunit, EaTERT, the 123 
kDa catalytic subunit, and a 43 kDa telomerase accessory protein, a La 
homolog that is important for nuclear retention and anchorage to an apparent 
end-replication complex (149,154).  Together, these proteins form the 
functional ~230 kDa telomerase RNP in vivo. 
Here, we used gel filtration and EM to examine purified E. aediculatus 
telomerase RNP and its binding to a model chromosome containing the E. 
aediculatus consensus 3′ overhang T4G4T4G4T4G2 (1,155).  Size exclusion 
chromatography of telomerase compared to proteins with known 
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molecular weights suggests that purified E. aediculatus telomerase is active 
as a dimer in solution. EM examination of binding reactions revealed mostly 
globular telomerase complexes bound to DNA.  Comparison of particle size 
(projected area) to the globular protein apoferritin suggests that telomerase 
binds to telomeric 3′ ends as a dimer, and that higher order multimerization of 
these bound telomerases occurs, accordingly associating free DNA ends in 
vitro. 
 
MATERIALS AND METHODS 
Growth of E. aediculatus and Preparation of Nuclear Extracts   
E. aediculatus was grown under nonsterile conditions using 
Chlorogonium as the food source as previously described.  Cultures were 
grown in 5 gallon flasks with continuous aeration (156).  Nuclei were isolated 
by sucrose cushion gradient centrifugation, and nuclear extracts were 
prepared by Dounce homogenization, as previously described (155). 
Purification of E. aediculatus telomerase   
Telomerase was purified from nuclear extracts following the procedure 
described by Lingner and Cech (149).  In short, nuclear extracts (15 ml from 1 
× 109 cells) were chromatographed over a heparin sepharose column 
(Amersham Biosciences, Piscataway, NJ) using a linear gradient of 
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increasing potassium glutamate, and the telomerase containing fractions were 
pooled and concentrated using an Amicon stirred cell concentrator (Millipore, 
Billerica, MA).  Telomerase was purified from these enriched fractions by 
affinity chromatography using a bait oligonucleotide, 5′-biotin-
TAGACACCTGTTA-(rmeG)2-(rmeU)4- (rmeG)4- (rmeU)4-(rmeG)-3′ to trap 
telomerase onto Ultralink Neutravidin beads (Pierce Biotechnology, Inc., 
Rockford, IL).  Telomerase was displaced by a chase oligonucleotide that is 
complementary to the bait, and the chase was removed by extensive dialysis 
against reaction buffer (20 mM Tris Acetate (pH 7.5), 10 mM MgCl2, 50 mM 
potassium acetate, and 1 mM DTT) and concentrated.   
Gel Filtration   
An AKTA FPLC system equipped with a Superdex 200 10/300 GL 
column (Amersham) was used.  The column was equilibrated with 20 mM 
Tris-HCl pH 7.5, 200 mM potassium acetate, 10 mM MgCl2, 1 mM EDTA, 
10% glycerol and 1 mM DTT.  Affinity-purified telomerase was injected and 
the column was run at a rate of 0.4 ml/min at 4 ºC.  After 7 ml of void volume 
had passed through the column, 200 µl fractions were collected.  The column 
was calibrated three times using the high molecular weight calibration kit from 
Amersham (R2 = 0.9978).  Aldolase (158 kDa), Ferritin (440 kDa) and 
Thyroglobulin (669 kDa) were run at the same time on the Superdex 200 
column and their retention volumes were determined twice, in two separate 
runs, and fit to the curve y = -148.18x + 2124.4.  The marker protein 
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Catalase (232 kDa) was run as a separate control to validate the calibration 
curve, since it has a retention volume that would be similar to that of a 
telomerase monomer. 
Telomerase Quantification   
The telomerase was quantified by analysis of the RNA subunit by 
solution hybridization with a 32P-labeled probe for the E aediculatus 
telomerase RNA.  Quantities were normalized to RNA standards and the 
amount of telomerase RNP was determined according to the calculation: ng 
RNP = ng RNA / 64 kDa x 230 kDa, where the mass of the RNA subunit is 
known to be 64 kDa and the mass of the telomerase RNP monomer is 230 
kDa (149,154). 
DNA Manipulation   
Model telomeres were synthesized by a modification of the method 
described by Stansel et al. (69).  In short, the plasmid pRST5 (10 µg), was 
digested with BsmB1 to generate a 5′ overhang with the sequence TCCC.  
The linearized DNA was incubated with the Klenow fragment of DNA 
polymerase 1, 33 µM dTTP, and 0.4 mM dCTP to create a blunt end on one 
side of the linear DNA.  A 3′ overhang was generated by ligating either a 
telomeric DNA Ea_CM_22 (AGGGT4G4T4G4T4G2) or non-telomeric DNA 
(AGGGATTGAATGACTACGAAGATGAA) oligomer onto linearized pRST5.  
Ligation reactions contained 5 µg linearized pRST5, 5-fold molar excess of 5′ 
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phosphorylated oligonucleotide, T4 DNA ligase (200 U, New England Biolabs, 
Inc., Ipswich, MA) and T4 DNA ligase buffer (New England Biolabs) and were 
incubated at 25º C for 30 min. Excess oligonucleotide was removed by size 
exclusion chromatography using Sephacryl-400 (Promega).  DNA was 
deproteinized by the addition of 80 µg/ml proteinase K in 1% SDS followed by 
extraction with phenol/chloroform and concentration by ethanol precipitation.  
DNA was resuspended in 10 mM Tris-HCl (pH 7.6), 1 mM EDTA to give a 
final concentration of ~20 ng/µl.  Ligation efficiency was determined by 
treating ligated and unreacted linearized pRST5 with the Klenow fragment of 
DNA polymerase 1 and [α-32P]-dGTP and dATP and comparing the percent of 
incorporated dGTP.  Typically, we achieved 70% ligation efficiency.  
Telomerase Activity Assay and Catalyzed Extension of Model Telomeres  
The ability of telomerase to extend telomere model DNAs was 
determined by a modification of a primer extension assay (157).  Each 10 µl 
DNA extension assay contained 20 ng of DNA (see Figure 2.2B for details), 2 
fmol of purified telomerase, 2 µCi [α-32P]-dGTP (3000 Ci/mmol), 10 µM dGTP, 
50 µM dTTP, 20 mM Tris-acetate (pH 7.5), 50 mM potassium acetate, 10 mM 
MgCl2, and 1 mM DTT.  Reaction mixtures were incubated at 25º C for 30 min 
and quenched by the addition of 20 mM Tris-acetate (pH 7.5), 10 mM EDTA, 
1% SDS and 80 µg/ml proteinase K.  Extension products were recovered by 
ethanol precipitation and analyzed by electrophoresis on a 10 cm x 10 cm 4-
12% acrylamide gradient gel containing 7 M urea.  Dried gels 
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were imaged by phosphorimaging (Molecular Storm 860) and quantified using 
ImagQuant version 5.2.  The activity of telomerase in fractions eluted from the 
gel filtration column was similarly determined using a primer extension assay, 
where 50 µl of each fraction was reacted with 1 µM of the primer 5′-
AATGAATGACTACGATTTT-3′ at 25º C for 20 h.  The radiolabeled primer [α-
32P]-T10 was added to the quenching solution as a loading control and 
extension products were analyzed by electrophoresis on a 20 cm x 20 cm 
denaturing PAGE gel. 
Determination of Primer Km   
Km for telomerase binding to the telomere model DNA Ea_CM_22 or to 
a short, single stranded DNA primer, pEA22 (5′-T4G4T4G4T4G2) were 
determined by a DE81 filter-binding assay.   Affinity purified telomerase (0.5 
nM) was incubated with varying concentrations of primer (either pEA22, or 
Ea_CM_22), 50 µM dTTP, 10 µM dGTP, and 0.33 µM [α-32P]-dGTP (3000 
Ci/mmol) in telomerase reaction buffer for 30 min at 25º C.  Reactions were 
quenched by the addition of 50 mM EDTA and spotted onto DE81 filter paper.  
Unincorporated [α-32P]-dGTP was washed away with 0.5 M sodium 
phosphate, pH 7.0.  Filters were counted by liquid scintillation counting and 
the data was corrected by the subtraction of background binding to the filter 
using a telomerase negative reaction. Data were fit to the Michaelis-Menten 
equation using Sigma Plot.  
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Electron Microscopy 
Model telomeric DNA was diluted to 1 µg/ml in 10 mM HEPES pH 7.5, 
50 mM potassium acetate, 8% PEG, 2 mM magnesium acetate followed by 
addition of E. aediculatus telomerase to 0.7 µg/ml for 10 min at 37º C.  
Proteins were fixed onto the DNA with 0.6% glutaraldehyde and the mixtures 
were filtered through 2 ml columns of Bio-Gel A-5m (Bio-Rad Laboratories, 
Inc., Hercules, CA) that had been equilibrated with 0.01 M Tris-HCl (pH 7.6), 
0.1 mM EDTA.  Addition of spermidine to 2.5 mM and MgCl2 to 1 mM allowed 
for sample adsorption onto copper grids supporting thin, glow-charged carbon 
foils.  The samples were washed stepwise with 25%, 50%, 75% and 100% 
ethanol for 5 min followed by air-drying and rotary shadowcasting with 
tungsten (158).  An FEI Tecnai 12 electron microscope was used at an 
accelerating voltage of 40 kV to photograph images on plate film or a Gatan 
4K x 4K CCD camera.  Micrographs for publication were captured from plate 
film negatives using a Nikon SMZ1000 digital camera and morphometry 
measurements were done using ImageJ version 1.29 (National Institutes of 
Health). 
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RESULTS 
Gel Filtration Suggests Telomerase Dimers 
E. aediculatus telomerase was purified by the method of Lingner and 
Cech (149).  The total fold purification of the affinity-purified fractions could 
not be determined due to very low yields as well as the large amount of BSA 
used in the purification procedure. However, we estimated the telomerase to 
be approximately 50% pure, as reported previously for the purification of a 
much larger culture with much higher yields (149).   
The quality of the purified telomerase was analyzed by silver staining 
of SDS-PAGE gels (Figure 2.1). Bands corresponding to all known E. 
aediculatus subunits were seen (120 kDa TERT, 64 kDa TR, and p43 
doublet) as well as bands for known polypeptide contaminants (BSA and 
polypeptides 35 and 37) (149).  The interface between the stacking and 
separating gels (stacking interface) is shown as a possible site of protein 
precipitation. Additional bands were seen that were likely polypeptide 
contaminants, but because samples were very dilute, it was not possible to 
determine the stoichiometry of these contaminating proteins with respect to 
telomerase. Nevertheless, these proteins did not appear to interfere with 
telomerase activity, which was robust in all assays, and because there was no 
protein observed in the binding of EM to nontelomeric DNA templates, we do 
not believe that these contaminants interfered with the telomerase EM binding 
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Figure 2.1: Affinity-purified telomerase fractions were separated on 10% 
polyacrylamide gels and stained with silver.  
The sample in lane A was run twice as long as the sample in lane B. Sizes of 
molecular mass markers that were run with the samples are given in 
kilodaltons at the left. Locations of known polypeptides, DNA, and RNA are 
indicated (arrows). The interface between the stacking and separating gels 
(stacking interface) is also indicated as a possible site of protein precipitation. 
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experiments (results discussed below). Indeed, when Hammond et al. cross-
linked partially purified E. aediculatus to 32P-radiolabeled single-stranded 
telomeric DNA, only one type of protein-primer product was observed (159).   
The oligomeric state of the telomerase was determined by gel filtration on a 
Superdex 200 column. The fractions were assayed for E. aediculatus 
telomerase RNA (EaTR) content and for telomerase activity (Figure 2.2).  The 
retention volume of telomerase was compared to that of four marker proteins 
with known molecular weights.  The EaTR content peaked in retention volume 
11.6 ml, corresponding to an approximate molecular weight of 400 kDa, 
whereas the telomerase activity peaked in retention volume 11.2 ml, 
corresponding to an approximate molecular weight of 457 kDa.  If the shape 
of the telomerase particle does not greatly deviate from spherical, then this 
result would be consistent with the predicted mass of a telomerase dimer of 
~460 kDa (the molecular weight of telomerase is ~230 kDa ), a result that is in 
agreement with gel filtration chromatography of E. aediculatus nuclear 
extracts done previously by Aigner, et al. (150). The slight offset between the 
peak RNA content and the peak telomerase activity could then be due to 
some dissociation of telomerase subunits during the gel filtration experiments, 
which could also account for the lower activity of the fractions with smaller 
apparent molecular weight. These data suggest, therefore, that E. aediculatus 
telomerase may be an active dimer in solution. 
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Figure 2.2: Telomerase profile which suggests a dimer in solution.  
Elution profile of affinity-purified Euplotes telomerase chromatographed on a 
Superdex 200 gel filtration column. The amount of telomerase (line graph) in 
each fraction collected was determined by detection of the RNA subunit 
EaTR. Fractions that contained telomerase were then assayed for telomerase 
activity (bar graph), as described in Experimental Procedures. Only fractions 
with activity above background are shown. Amounts and activities are shown 
relative to the highest value, which was set to 100%. 
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Synthesis of a Model Telomere 
A synthetic model telomere was prepared by linearizing the plasmid pRST5 to 
generate a 3.5 kb DNA with one end terminating in 550 bp of (TTAGGG) 
repeats and a 5′ overhang.  A single strand oligonucleotide was ligated to this 
end to generate a 22 nt 3′ overhang consisting of the E. aediculatus repeat 
T4G4T4G4T4G2 (Ea_CM_22, Figure 2.3A) (Methods and Materials).  A control 
DNA with a non-telomeric overhang was similarly prepared using the random 
sequence single strand oligonucleotide ATTGAATGACTACGAAGATGAA.  In 
these reactions, we routinely achieved 65-70% ligation efficiency. 
Telomerase can Extend the Model Telomere 
To determine if the model telomere Ea_CM_22 could act as a 
telomerase primer, we examined the ability of telomerase to extend the model 
DNA using [α-32P]-dGTP in the reaction mixture.  Reaction products were 
analyzed by electrophoresis on an acrylamide gradient gel for the 
incorporation by telomerase of [α-32P]-dGTP into the substrate DNAs. We 
found that Ea_CM_22 was an efficient substrate while linear pRST5 DNA that 
did not contain a telomeric overhang was not a substrate (Figure 2.3B), and 
determined that the Km for telomerase binding to Ea_CM_22 was 4 nM as 
compared to 14 nM for a 22-nucleotide primer used as a control, , which is 
comparable to the reactivity of primers with any of the possible permutations 
of the telomeric sequence (157,160).  
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Figure 2.3: Telomerase can extend a model chromosome.   
(A) Synthesis of a Euplotes model telomere DNA (Ea_CM_22).  Details of the 
enzymatic steps are in Methods and Materials. (B) Affinity-purified telomerase 
was incubated with dTTP and [α-32P]-dGTP and either Ea_CM_22 (lane 1), 
Ea_CM_22 and RNase A (lane 2), linear pRST5 with a nontelomeric end  
(lane 3), linear pRST5 with a nontelomeric end and RNAse (lane 4), linear 
pRST5 (lane 5) or linear pRST5 with RNase (lane 6).  Lane 7 is a marker for 
linear pRST5. 
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Visualization of Telomerase Bound to Telomere Models 
Purified E. aediculatus telomerase was incubated with the 3.5 kb model 
telomere DNA Ea_CM_22 or the linear control DNA with the random 
sequence overhang.  The reaction conditions used were consistent with those 
used to show that the purified telomerase was able to extend the model 
telomere, but were varied slightly to achieve the best conditions for visualizing 
protein-DNA complexes by EM.  Alternative permutations of the telomerase 
repeat sequence were not studied because it has been previously shown that, 
while telomerase processivity is affected, telomerase is able to bind to and 
utilize primers containing very few or no telomeric nucleotides at the 3’ end 
(161).  Thus, binding reactions were performed for different reaction times (1 
to 20 min) at varying temperatures (4º C, 25º C, 37º C) and protein:DNA 
molar concentrations (5:1 to 14:1) and in the presence or absence of PEG, a 
molecular crowding agent.  Optimum conditions included using a 7.5:1 molar 
concentration of telomerase to DNA in the presence of 8% PEG for 10 min at 
37º C.  The resulting complexes were fixed with glutaraldehyde and examined 
by EM. 
When E. aediculatus telomerase was incubated with the model 
telomere and prepared for EM, an array of telomerase-DNA complexes were 
observed (Figure 2.4).  The most common species consisted of a single 
model telomere DNA bound at one end by telomerase (Figure 2.4A-C).  Also 
present were complexes containing two or more model telomeres, each 
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Figure 2.4: Visualization of Euplotes telomerase bound to a model 
telomere substrate.  
E. aediculatus telomerase was incubated with a 3 kb model telomere DNA 
(Figure 2.3), then prepared for EM by fixation with glutaraldehyde, mounting 
on carbon coated EM grids, and rotary shadowcasting with tungsten (Methods 
and Materials).  Telomerase bound at one end of the model telomere (A-C). 
Examples of two (D, E) or three (F,G) model telomere DNAs bound together 
at one end by a telomerase complex.  Images shown in reverse contrast.  Bar 
is equivalent to 500 bp. 
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with one end synapsed to the other DNA by a large commonly-bound 
telomerase complex (Figure 2.4D-G).  Less frequently seen were DNA 
molecules containing one or more internally-bound protein complexes (not 
shown).   
Five separate reactions were scored with an average of 71 molecules 
counted per experiment (Table 1).  In total, 46% of all telomere model DNAs 
showed a telomerase complex bound at one end.  When the non-telomeric 
overhang was employed, only 4% of the ends showed protein bound.  Thus 
the telomeric 3′ end of the model telomere is bound specifically by one or 
more telomerase molecules.  Quantification of the protein-bound DNA 
molecules revealed an average of 45% with a telomerase complex bound to a 
single model telomere end, whereas 22% and 21% had two and three DNAs 
respectively associated at their ends through a large telomerase complex, 
likely a telomerase oligomer.  Telomerase was observed bound non-
specifically to internal DNA sequences within the model telomere in 12% of 
the DNAs.  Occasionally, very large DNA-protein aggregates were seen, and 
were not included in the scoring.  Using a lower concentration of telomerase 
in the binding reactions alleviated this problem somewhat, although conditions 
for binding required that the telomerase concentration could not be too low. 
From these observations we conclude that E. aediculatus telomerase 
binds to the 3′ consensus overhang of the model telomere and that it is also 
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Table 2.1: Percent of model telomere DNAs bound at their end by a 
telomerase complex.  
Reaction Molecules counted End-bound complexes 
1 104 52% 
2 109 47% 
3 45 40% 
4 43 42% 
5 54 50% 
Average 71 46% 
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capable of self-association, consequently bringing two or more DNA ends 
together in vitro.  This, however, should not necessarily be taken as 
suggesting that telomerase is able to synapse two chromosome ends in vivo. 
Telomerase Oligomerization 
The degree of oligomerization of the bound telomerase complexes was 
determined using a variation of a method used in our previous studies 
(162,163).  A large protein standard of known mass is mixed with the sample 
and the size (projected area in the micrographs) of the standard is compared 
to the projected area of the protein bound to the DNA.  If the standard and 
sample are of similar size and shape, molecular weight estimates can be 
derived that can differentiate with certainty between different oligomeric states 
of the protein bound to DNA.  In this study since there was a significant 
amount of free telomerase in the background on the grids, the molecular 
weight standard was adsorbed to separate grids and the standard and sample 
processed for EM side-by-side.  This can be expected to add some but not a 
significant additional measurement error.  
The telomerase complexes on DNA appeared mostly globular, and 
inspection showed that apoferritin (443 kDa) was close in size (projected 
area) to the class of telomerase particles most frequently seen at the ends of 
a single model telomere DNA, suggesting that these particles may consist of 
telomerase dimers.  Photographs of fields of apoferritin molecules were taken 
and the mean projected area of 30 examples was measured (Figure 
 52 
2.5E).  The average projected area of the apoferritin was set to an arbitrary 
value of 100 units.  On the basis of the mass of a telomerase monomer, the 
predicted projected area relative to apoferritin should be 64 units as 
determined by the formula: mass of telomerase/mass of apoferritin = (area of 
telomerase/area of apoferritin)3/2. 
Similarly, the predicted projected areas of a dimer, trimer, tetramer and 
pentamer would be 102, 134, 162, and 188 units respectively.  These sizes 
were then compared to measurements of projected areas of telomerase 
complexes bound to the end of a single model telomere DNA (Figure 2.5A-D).  
A histogram representing the calculated mass derived from such 
measurements is shown in Figure 2.6.  The mean projected area of the 
complex was thus 101(± 23) units and the mean calculated mass value was 
455(± 160) kDa (n = 34).  Assuming the telomerase complex binds only to the 
consensus 3′ overhang, we subtracted ~8.6 kDa for the single strand 
sequence [T4G4]2TTTTGG which resulted in a mass of 447(±151) kDa.  
Although the distributions may have been broadened by the slightly oblong 
shape of the telomerase and thus by variations in projections of the 
telomerase particles, these data suggest that the telomere end was most 
commonly bound by a dimer of telomerase.  This finding is consistent with the 
size of telomerase determined by gel filtration here and previously reported 
(150). 
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Figure 2.5: Estimation of the oligomeric state of DNA-bound telomerase 
by direct size comparison.  
Telomerase complexes at the ends of single model telomeres (A-D) or joining 
two model telomeres (F-H) were compared to the size of apoferritin particles 
(E).  The telomerase DNA complexes and apoferritin were prepared for EM 
side-by-side on separate EM supports.  Shown in reverse contrast, bar is 
equivalent to 500 bp. 
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Figure 2.6: Histogram of the calculated mass of telomerase at the end of 
a single model telomere.   
The calculated mass values derived from measurements of the projected 
areas of telomerase complexes bound to the end of a single model telomere 
DNA are shown.  The mean calculated mass value (solid grey line) was 447 
kDa with a standard deviation of 151 kDa (s, dotted grey lines).  Molecular 
weights of a monomer (230 kDa), dimer (460 kDa), trimer (690 kDa) and 
tetramer (920 kDa) of telomerase are indicated by arrows. 
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For the class of telomerase particles bound at the junction of two 
model telomeres, the protein mass was frequently much larger than 
apoferritin.  The projected areas of a subset (n = 19) of the smallest particles 
was measured, however, revealing a broad distribution of calculated mass 
values (Figure 2.5F-H).  When compared to apoferritin (set to 100 units) the 
mean projected area of these particles was 176(± 64) units.  After subtracting 
~17 kDa for the DNA content this resulted in a mean calculated mass of 
1061(± 569) kDa.  Although this value is sufficiently broad to encompass a 
dimer (460 kDa) or trimer (690 kDa) of telomerase, the data seem more likely 
to suggest that, at a minimum, two dimers of telomerase, each associated 
with a model telomere, bind to form a tetramer (920 kDa) in vitro.  Indeed, for 
this class of particles one could occasionally distinguish a region of separation 
between two globular particles, each the size of a dimer, that is consistent 
with a dimer-of-dimers (Figure 2.4D-G). 
 
DISCUSSION 
In this study, E. aediculatus telomerase was isolated from nuclear 
extracts using affinity chromatography with an antisense oligonucleotide. 
Although electrophoretic analysis of fractions revealed several contaminants, 
these did not interfere with telomerase activity, which was robust, or with our 
EM binding experiments, as seen by the lack of protein binding to control 
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DNA templates.  
The molecular mass of telomerase, determined by gel filtration, was 
consistent with the mass of a dimer. When the telomerase particle was 
visualized by EM, its shape was seen to be mostly globular, and inspection of 
the telomerase bound to its substrate showed that it bound predominantly as 
a dimer. Taken together, we find these observations to be convincing 
evidence that E. aediculatus telomerase dimerizes in solution and that it binds 
to telomeric DNA as a multimer, most likely as a dimer.  
It was also shown by EM and a modified primer extension assay that 
telomerase specifically binds to and extends the consensus telomeric 3'-
overhang in vitro. Further, when end-to-end pairing of two DNA molecules 
occurred, the telomerase complex was likely a tetramer or larger oligomer.  
These findings are consistent with a model of processive telomere 
reverse transcription consisting of two cooperating telomerases that bind to 
and extend a single DNA substrate. The data do not support an obligate 
parallel extension model of telomerase cooperation, where two active sites 
within two different but associated telomerase RNPs simultaneously extend 
two separate chromosome 3'-ends (145,148), although it is still possible that 
two dimers of telomerase can coordinate to extend two separate but adjacent 
chromosome ends, such as sister chromatids.  
Rivera et al. showed that a dimeric human telomerase can 
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processively utilize a single template (164), which argues against the template 
switching model in humans, where the two catalytic sites would act 
sequentially to elongate a single telomere 3'-end (145). Nevertheless, 
Euplotes is an evolutionarily very distant species, and it is still possible that 
the template switching model or the DNA anchor site model, where one 
telomerase RNP template anchors the dimer while the other template is used 
for reverse transcription (152), or combinations of these models may exist.  
This study is the first visualization of intact telomerase bound to a DNA 
substrate, and it provides the first direct proof of telomerase RNP 
multimerization in E. aediculatus.  
CHAPTER 3: ELECTRON MICROSCOPIC VISUALIZATION OF YEAST 
TELOMERASE RNA SUPPORTS MFOLD PREDICTIONS OF SECONDARY 
STRUCTURE 
 
INTRODUCTION 
Telomere sequences are lost during cell division, due to the ‘end-
replication problem’ (22,23), oxidative damage (25), and possible nucleolytic 
processing (24).  In cells with indefinite replicative potential, leading strand 
telomeric repeats can be restored by the ribonucleoprotein telomerase (29), 
while the lagging strand is concurrently elongated by the standard replicative 
machinery (30).  In Saccharomyces cerevisiae, the catalytic protein subunit of 
telomerase (EST2) uses the template sequence in the telomerase RNA 
(TLC1) to synthesize telomeric DNA by reverse transcription (37,41).   
Whereas the sequences of the catalytic subunits are conserved among 
ciliates (138), yeast and mammals (37), the sequences and sizes of the RNA 
components are highly variable (41,43,44,165,166).  In budding yeasts, there 
is a striking divergence in the sequence and size of the telomerase RNAs.  
Consequently, the lack of information has led to complications deducing their 
secondary structure.  Recently, a detailed working model for the secondary 
structure of the S. cerevisiae telomerase RNA, TLC1, was proposed (44,165) 
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using mfold predictions of energetically favorable RNA conformations (167) 
coupled with genetic and phylogenetic data from four species of 
Saccharomyces. This model proposed that the telomerase RNA consists of a 
central catalytic core containing the RNA template and Est2p-binding region, 
plus three long quasihelical RNA arms that bind Est1p (168), the Ku 
heterodimer (169), and the Sm heteroheptamer (170) (Figure 3.1A).   
To test this model, we used EM to directly visualize a 1261 nt TLC1 
RNA, as well as a 1133 nt deletion mutant (∆∆) proposed to have truncation 
of the longest RNA helix (44), Figure 3.1).  Consistent with the mfold 
predictions, most of the RNA molecules that were visualized contained two or 
three ‘arms’.  In addition, a nano-scale ‘biopointer’ was used to ‘point to’ a 
biotin moiety attached to an oligonucleotide (oligo) that was complementary to 
the RNA template region (171).  We found that in the majority of molecules, 
the biotinylated oligo was most often located at the center of the RNA. 
In a subsequent study, deletion mutagenesis that reduced the 1,157-
nucleotide (nt) TLC1 RNA to a size smaller than the 451-nt human RNA, but 
retained its function in vivo, demonstrated that the RNA serves as a flexible 
scaffold for the protein subunits, described as 'beads' (proteins) on a 'string' 
(RNA), and that the long protein-binding arms are not essential for the RNA to 
serve its scaffolding function (45).  This differs markedly from the best-studied 
ribonucleoprotein enzyme, the ribosome, where the RNAs have specific 
three-dimensional structures that orient the functional elements (172). 
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Figure 3.1 A model of S. cerevisiae telomerase RNA secondary 
structure2. 
(A). Two forms of TLC1 with different 3’ ends (~1261 nt and 1167 nt (boxed)) 
are hypothesized to be precursor and mature forms, respectively 
(170,173,174).  Phylogenetic data for each nucleotide (legend, boxed) were 
derived from alignment of TLC1 from Saccharomyces cerevisiae, paradoxus, 
mikatae and bayanus. Proteins that bind to TLC1 RNA are indicated and 
arrows indicate positions within the RNA to which they bind.  A dashed box 
indicates the central core region containing the template, template boundary, 
and proposed Est2p binding regions, necessary for telomerase RNA 
enzymatic function.  The template used for reverse transcription and the Sm7 
complex binding site are known to be single-stranded RNA regions.  (B). 
Schematic showing the nucleotide replacements in the TLC1 truncation 
mutant (∆∆). Nucleotides 22–102 were replaced with the sequence (CG)5, 
predicted to pair with the (CG)5 that replaced nucleotides 846–914 on the 
other side of the predicted terminal arm. 
 
                                            
2 Adapted from Zappulla D. C, et al. (2004) Proc. Natl. Acad. Sci. U. S. A.101 (27) 10024-29. 
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3 Adapted from Zappulla D. C, et al. (2004) Proc. Natl. Acad. Sci. U. S. A.101 (27) 10024-29. 
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MATERIALS AND METHODS 
In vitro TLC1 RNA Expression and Purification.   
The TLC1 RNA was transcribed in vitro from plasmids pT7-TLC1 (1261 
nt; a gift from Art Zaug) and pDZ118 (∆22-102::(CG)5 ∆846-914::(CG)5) using 
the following transcription conditions in a 1 ml reaction at 37 ºC for 1 hour: 20 
µg/ml plasmid DNA template (linearized with FokI), 40 mM Tris pH 7.5, 12 
mM MgCl2, 4 mM NTPs, 2 mM spermidine, 10 mM DTT, 0.4 µg/ml inorganic 
phosphatase and T7 RNA polymerase (~10 µg/ml).  The full length RNA was 
then purified by continuous elution electrophoresis through a tube- shaped, 
denaturing 4% polyacrylamide gel (2.8 cm diameter x 6 cm long) using a 
Model 491 Prep Cell electroelution apparatus (Bio-Rad, Hercules, CA) run at 
12 W of constant power.  Elution buffer consisted of 3 M urea, 0.5X TBE 
buffer and the flow rate was 1 ml/min.  TLC1 RNA fractions were then 
concentrated to approximately 300 µg/ml (0.5 µM) by centrifugal filtration in 10 
mM HEPES pH 7.0 and stored at -80 ºC.  For RNA refolding, TLC1 was 
heated to 94 ºC for 5 min in 10 mM HEPES pH 7.0, 1 mM EDTA and 150 mM 
NaCl, put into a 0ºC water bath and subsequently stored at -80ºC in aliquots 
for EM. 
Synthesis of biopointers.  
Nano-scale biopointers were prepared as previously described (171).  
In brief, a 179 bp region of pBluescript ® II S/K (+) Phagemid Vector 
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(Stratagene, Inc.) was amplified between the T7 and T3 promoters by PCR 
with one of the two primers biotinylated.  The DNA was purified by gel 
exclusion chromatography and mixed with a 10-fold excess of streptavidin.  
The streptavidin-bound DNAs (biopointers) were banded in CsCl (density 1.6 
g/ml) to equilibrium and the monomer biopointers collected. 
For the binding of biopointers to TLC1 RNA, folded TLC1 was 
incubated with a biotinylated DNA oligonucleotide complementary to the 
template, unbound oligo was removed from the solution by passing the 
complex though a Sephadex G-25 spin column (Roche), and then biopointers 
were added to the mixture.  This allowed visualization of the TLC1-
RNA:biotinylated-oligo complex by EM.  
Single-molecule Electron Microscopy.  
TLC1 RNA was diluted to 1 µg/µl in 10 mM Tris-HCl pH 7.5, 125 mM 
NaCl, 0.1 mM EDTA.  When required, biopointers were added to 0.5 µg/µl.  
Spermidine was added to sample mixtures to 2.5 mM and MgCl2 to 1 mM 
followed by adsorption onto copper grids supporting thin, glow-charged 
carbon foils.  The grids were washed stepwise with 50% ethanol in water for 
10 min and then 75% and 100% ethanol for 5 min followed by air-drying and 
rotary shadowcasting with tungsten (158).  Samples were visualized on a FEI 
Tecnai 12 electron microscope using an accelerating voltage of 40 kV.  Plate 
and digital photographs were taken and molecules measured, counted and 
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categorized using Gatan Digital Micrograph software.  
  
RESULTS 
Synthesis and folding of TLC1 RNA.  
A 1261 nt TLC1 RNA transcription product was synthesized in vitro 
using T7 RNA polymerase.  This RNA was purified by continuous elution 
electrophoresis on a denaturing polyacrylamide gel, and the RNA was then 
refolded by heat denaturation and quick or slow refolding in the presence of 
150 mM NaCl.  Native gel electrophoresis of refolded RNA demonstrated two 
predominant bands of similar mobility for the RNAs folded in all of these 
conditions (data not shown).  The quickly refolded RNA was used for the 
experiments presented here.  
Single-molecule electron microscopy of TLC1 RNA.  
Previous work has shown that long helices of RNA can be readily 
observed by EM (175). Since the TLC1 RNA secondary structure model 
proposes a molecule with three long, largely helical arms, TLC1 was 
examined by single-molecule EM (Figure 3.2).  An array of RNA 
conformations were seen, where the most common species consisted of two 
to four quasihelical arms protruding from an unstructured site on the RNA, 
giving it a ‘spider’ like appearance (Figure 3.2B-D).  Also present were 
 67 
Figure 3.2. Electron microscopy of TLC1 RNA. 
(A-D) Four representative examples each of TLC1 RNA molecules with 1,2,3, 
or 4 arms. Arrow in C indicates electron-dense RNA core.  (E). 
Representative structures observed from analysis of TLC1 harboring the 
truncation in the terminal arm (∆∆, as described in Figure 3.1b). Arrow 
indicates lower electron density in the RNA core.  (F) Diagram of a biopointer 
consisting of a 179 bp DNA bound to a molecule of streptavidin protein.  (G-
J). Representative examples of a biopointer alone (G), or bound to the center 
(H-I) or to the helical arm (J) of the TLC1 RNA.  Arrows indicate the 53 kDa 
streptavidin protein. 
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molecules containing one arm (Figure 3.2A) or no arms (data not shown).  
Three separate preparations were scored, with more than 100 molecules 
counted per experiment (Figure 3.3A).  The observed distribution may 
underestimate the true number of arms in the RNA, since molecules may land 
on the grid with arms overlapping, sticking up so that they do not appear as 
arms, or kinked back on themselves in such a way that they are no longer 
discernable.  Molecules that had an ambiguous structure or appeared 
globular (and could not be confirmed to be RNA) were not counted.  The RNA 
construct harboring truncation of the terminal arm (∆∆), which is functional in 
vivo (44), Figure 3.1B), was also visualized by EM (Figure 3.2E).  The 
distribution of apparent arms was slightly shifted towards a greater number in 
this mutant molecule (Figure 3.3A).  Thirty 3-armed ∆∆ TLC1 RNA molecules 
were measured from the center of the RNA mass to the tip of each arm.  The 
longest arm had a mean length of 30.5 ± 4.3 nm with the other arms being 
24.5 ± 3.7 and 20.2 ± 3.6 nm.  Using 0.27 nm as the axial rise per nucleotide 
(176), this correlates with arms of 113, 91 and 75 bp.  In remarkable 
agreement, the model of Figure 3.1B predicts the equivalent of 114 bp in the 
truncated terminal arm, 99 bp in the Ku arm, and 74 bp in the Est1p arm.  (We 
count an unpaired base in an internal loop as contributing the equivalent of 
one bp in length.  Because the structures and lengths of such loops cannot be 
predicted, this represents a source of uncertainty in the correlation of arm 
length measured by EM with our model).  Surprisingly, measurement of thirty-
five 3-armed molecules of full-length TLC1 gave arm length 
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Figure 3.3. Histograms summarizing the EM data. 
(A).  The number of apparent arms per molecule of TLC1 were counted  and 
compared to the number of apparent arms per molecule of the deletion 
mutant (∆∆).  (B).  Histogram indicating the percentage of instances when 
biopointers (BP) were observed at the center of RNA molecules or arms. 
 71 
 
 72 
measurements of 29.1 ± 4.1 nm, 23.4 ± 3.7 nm, and 18.3 ± 3.6 nm, 
indistinguishable from those of the ∆∆ molecules.  This result is addressed in 
the Discussion. 
 ‘Biopointers’ indicate the template is at the center of the RNA.   
The nano-scale ‘biopointer’ used here consists of a short, stiff 179 bp 
DNA rod with a single streptavidin tetramer bound to one end (171), Figure 
3.2F).  Biopointers are easily seen in the EM preparative method used here 
(Figure 3.2G), yet are small enough to not obscure the molecule or complex 
being tagged.  The streptavidin tetramer can then bind and ‘point’ to biotin 
molecules present on the macromolecules. 
In this study, we have used biopointers to identify a biotinylated DNA 
oligonucleotide bound to the template region of TLC1 RNA, with the aim of 
elucidating the relative position of the template.  When the biotinylated 
template oligo was annealed to TLC1, biopointers were seen bound to the 
RNA 30% of the time.  In control experiments, where TLC1 was incubated 
with a biopointer in the absence of the biotinylated template oligo, biopointers 
were seen bound to the RNA only 5% of the time. 
The vast majority of biopointers were observed bound to the centers of 
the RNAs (Figure 3.2H-I).  Less often, biopointers were observed bound to 
the ends of the RNA arms (Figure 3.2J).  Specifically, 32 ± 11% of 3-armed 
RNAs and 41 ± 1% of 4-armed RNAs had a biopointer pointing to the center 
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of the molecule, whereas 7 ± 7% of 3-armed RNAs and 16 ± 8% of 4-armed 
RNAs had a biopointer pointing to the end of an arm (Figure 3.3B).  
Interestingly, there seemed to be a moderate increase in binding of the 
biopointers to the 4-armed RNAs than to the 3-armed RNAs, both at the 
center of the molecules and at the ends of the RNA arms.  A possible 
explanation for this may be that the 4-armed RNAs were more loosely 
structured than the 3-armed structures, such that the template region was 
able to migrate; or alternatively that it is more accessible for binding in vitro.  
In summary, the biopointers show the template to be generally within the 
central core of the multi-armed RNA molecules visualized by EM. 
 
DISCUSSION 
Electron microscopy supports the existence of several helical arms 
protruding from a central core.  The mean distribution of the number of arms 
seen supports the prediction of three long quasi-helical RNA arms, although 
the results are not conclusive.  Since RNA molecules with long quasi-helical 
arms can be trapped on the grid with arms pointing out in three dimensions or 
with arms overlapping, the number of arms observed were likely less than 
what would have been seen if the TLC1 RNA was properly stretched out over 
the two-dimensional surface.  Thus, the abundance of two-armed molecules 
for TLC1 may be overestimated in this data.  Alternatively, it could reflect the 
incomplete re-folding of the RNA molecules from the denatured state. 
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The latter may also be the case for the 4-armed molecules observed.  
The observation that truncation of the terminal arm had no net effect on 
the length of any of the TLC1 arms is curious.  It is possible that the base of 
the longest arm collapsed into the central body of the RNA, giving rise to an 
electron-dense unstructured region (arrow, Figure 3.2C as contrasted to 
arrow, Figure 3.2E); or that the longest arm was able to fold back so that its 
terminus interacted with the central core, resulting in an arm half as long, but 
twice as thick (which we were not able to measure).  Such compaction may 
have caused the apparent underestimation of the terminal arm length.  In the 
terminal arm truncation mutant, nucleotides that are proposed to form an 
interrupted helix were replaced by 10 Watson-Crick C-G base pairs.  The 
shortening and/or insertion of this sequence may have caused the dynamics 
of the terminal arm to be affected such that it became more readily extended.  
This would explain the excellent agreement between expectation and 
measurement for the longest arm of the ∆∆ mutant RNA.  Such a trend for the 
more frequent extension of arms of this mutant is also supported by the fact 
that more arms were observed in the terminal arm truncation mutant (Figure 
3.3A) than in the wild-type RNA. 
In summary, these results support the overall model of TLC1 structural 
flexibility, such that the yeast telomerase RNP, in contrast to the ribosome, is 
a rather loosely ordered complex of RNA and protein subunits (44,45)..
CHAPTER 4: REPLICATION FORK REGRESSION IN REPETITIVE DNA’s  
 
INTRODUCTION  
Repetitive DNA sequences found in the human genome consist of 
repeat units ranging from mono-, di-, and tri-nucleotide repeats to long 
repeating units found in Alu and LINE elements. Overall, repetitive DNA 
makes up approximately 30% of the human genome with the  Alu  and LINE 
elements constituting the greatest amount (177). The short sequence units 
which include the triplet and telomeric repeats are of particular interest due to 
the high number of repeats per unit length of DNA which may bestow unique 
biological and physical properties.  
The triplet repeats which include (CGG)n•(CCG)n, (CAG)n•(CTG)n and 
(GAA)n•(TTC)n have been implicated in numerous human hereditary diseases, 
a hallmark of which is the appearance of disease pathology when the repeat 
blocks expand beyond certain tight length thresholds generally exceeding 35 
repeats (178).  In addition, tetrameric (CCTG)n•(CAGG)n (179), pentameric 
(AATCT)n•(AGATT)n (180) and dodecameric (C4GC4GCG)n•(CGCG4CG4)n 
(181) repeats have been linked to the genetic diseases myotonic dystrophy 
type 2 (DM2), spinocerebellar ataxia type 10 (SCA10) and progressive 
myoclonus epilepsy, respectively. The length of disease-related repeats can 
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vary from as little as a few repeats in normal individuals to up to 40 kb in the 
SCA10 expansions (182).  Whereas the exact mechanism of repeat 
expansion in humans remains unknown, one feature common to all expanded 
repeats is that they are highly unstable above a threshold of approximately 
100–200 bp (183).    
Telomeric repeats which are composed of the hexameric unit TTAGGG 
in all mammals and many animals (TTTAGGG in plants) are essential for 
chromosome stability and regulating the replicative lifespan of somatic cells 
(184).  These repeats comprise the DNA component of the telomere (3,4), a 
nucleoprotein structure which protects the ends of chromosomes and enables 
cells to distinguish telomeric ends from random double-strand (ds) break ends 
(16,185).   
Telomeric repeats can reach lengths of 15 kb in humans and as much 
as 150 kb in plants. In the absence of telomerase, a telomere reverse 
transcriptase, telomeric repeat sequences are gradually lost during cell 
division, due in part to the ‘end replication problem’ that results from the 
inability of the lagging strand to be replicated to the very end of the 
chromosome (22,23).  Large blocks of telomere repeat sequences can also 
be lost stochastically when the proteins required for end protection functions 
are disrupted, or problems are encountered during DNA replication or repair 
(184). In the absence of telomerase, certain human cancer cells have been 
shown to exhibit highly unstable telomeres (ALT phenotype) with 
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rapid increases or decreases in telomere lengths (54,186,187).  
Evidence suggests that the nature of repetitive DNA may itself be a 
causative factor in mutagenesis (188-191).  The relative instability of long 
blocks of short repeats may also be related to inherent difficulties of the DNA 
synthesis machinery in replicating through this type of DNA.  A large body of 
evidence shows that there is frequent polymerase pausing in triplet blocks, 
that both the lagging and leading strands may form hairpins, G-quartets or 
triplex structures when comprised of certain repeats, that the polymerase can 
slip during synthesis through repeat tracts, and that primer template 
misalignment can occur as a result of hairpins in the template strands 
(reviewed in (183,192-194).  Also, telomeric sequences undergoing 
replication have the potential of forming G-quartets. These impediments to the 
replication fork could then give rise to repeat expansions or deletions due to 
reiterative DNA synthesis or replication restart via recombination 
intermediates.  Indeed, recent evidence in E. coli suggests that a major 
mechanism for (CAG)n·(CTG)n repeat instability is replication restart, via a 
Holliday junction ‘chickenfoot’ intermediate, after DNA polymerase pausing 
and the resultant collapse of the replication fork (131,195). 
Relatively little is known about the replication of mammalian telomeric 
DNA.  Over expression of the telomeric binding proteins TRF1 and TRF2 has 
been shown to lead to replication fork stalling in vivo (196), and in vitro human 
telomeric DNA is replicated much less efficiently than non-telomeric DNA 
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(196) and unpublished data).  Further in addition to the normal replicative 
helicases present at forks, the RecQ helicases WRN and BLM, implicated in 
premature ageing diseases,  have been shown to be important for proper 
telomere replication and maintenance in human cells (94,102,103).  These 
helicases have been shown to unwind G quartets and four-stranded junctions 
similar to chickenfoot structures (107-109,111,113,197) suggesting that these 
or other secondary structures unique to telomeric repeats may form and 
present barriers to replication.  
These observations suggest that the polymerase machinery is much 
more prone to pause or stall during replication of long blocks of short repeats. 
In the absence of stabilizing proteins, this could lead to fork regression and 
the generation of four-stranded chickenfoot molecules (pictured in Figure 
4.2B).  Resolution of these chickenfoot intermediates could lead to restoration 
of replication but inappropriate resolution could lead to expansion or 
contraction of the DNA tracts or possibly the generation of extrachromosomal 
repeat DNA.  
To begin testing this hypothesis, we generated model replication fork 
templates which mimic a replication fork that has transited a long block of 
either telomeric repeats or triplet (CTG) repeats.  Examination of the structure 
of this stalled fork by EM provided a means of detecting forks which may have 
either fully regressed or partially regressed leading to a chicken foot structure.  
Previously we used this model system with sequences  which were not 
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repetitive and we showed that chickenfoot structures could be observed when 
p53 was present to trap these forms during fork regression (198).  In this 
paper, we show that nearly half of all repeat-containing templates had 
spontaneously regressed, with a large percentage of molecules forming 
chickenfoot intermediates.  These four-way junction molecules  were not 
observed in the absence of p53 in our previous study of non-repetitive  DNA 
(198).  We discuss a model in which repetitive DNA is highly slippery with a 
high tendency to generate long-lived chickenfoot structures and the implicit 
implications related to triplet and telomere DNA stability. 
 
MATERIALS AND METHODS 
Construction of plasmids 
Complementary oligonucleotides (oligos) 1) 5′-
TCGAAGACTTAGGGGCTGAGGTT-3′ and 2) 5′-
CCCTAACCTCAGCCCCTAAGTCT-3′ containing a site for the nicking 
endonuclease N.BbvC IA (New England Biolabs, Beverley, MA) were 
annealed and cloned into the XhoI and BbsI sites of the plasmid pRST5 (69), 
to create pRST5NICK.  Dr. Y. H. Wang (UMDNJ) generously provided the 
plasmid pGEM(CTG)130, which was constructed by digesting the pSH2 
plasmid (199) with restriction endonucleases SacI and HindIII (New England 
Biolabs) to isolate the CTG fragment, and then cloning this fragment into the 
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same restriction sites in the plasmid pGEM3zf(+) (Promega Corporation, 
Madison, WI) (unpublished data).  Site-directed mutagenesis was performed 
on the plasmid pGEM(CTG)130, resulting in the creation of two sites for the 
restriction endonuclease BsmI (New England Biolabs) directly adjacent to, 
and on either side of, the CTG repeat tract.  During this process, some CTG 
repeats were lost, resulting in a tract length of [CTG]110.  The complementary 
oligos 1) 5′-TCAGCCAGGCCGAAAGAAAGAAAAGGACAGAGAAAGCC-3′ 
and 2) 5′-CTTTCTCTGTCCTTTTCTTTCTTTCGGCCTGGC-3′ were annealed 
and cloned into the BsmI and BbvCI sites of this plasmid, downstream of the 
CTG repeat tract, generating a 221 bp region devoid of A’s followed by a site 
for the nicking endonuclease N.BbvC IB (New England Biolabs).  During this 
process, more CTG repeats were lost, generating the plasmid p(CTG)60NICK 
with a final tract length of [CTG]60.  Plasmid constructs were confirmed by 
DNA sequencing (The DNA Facility, Office of Biotechnology, Iowa State 
University). 
Construction of replication fork templates 
Model replication forks were synthesized by a modification of the 
method described by Subramanian et al. (198).  In short, the plasmid 
pRST5NICK was digested with N.BbvC IA to generate a nick in the G-rich 
strand at the start of the telomeric tract [TTAGGG]96.  Similarly, the plasmid 
p(CTG)60NICK was digested with N.BbvC IB to generate a nick in the A-rich 
strand at the start of the 221 bp region containing the CTG repeat tract.  
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The nicked DNA was incubated with the Klenow fragment (exo-) of DNA 
polymerase 1 (New England Biolabs), and 0.5 mM each dTTP, dATP, dGTP 
(telomeric template) or dGTP, dCTP, dATP (CTG template) to generate a 
single strand (ss) tail by strand displacement of the repeat tract.  The ss tail 
was then converted to a double strand (ds) tail by annealing a 228-fold molar 
excess of the oligo 5′-CCCTAACCCTAACCCTAACCCTAA-3′ (telomeric 
template) or a 120-fold molar excess of the oligo 5′-CTGCTGCTGCTGCTG-3′ 
(CTG template) to each template for 30 min at 37 ºC in 100 mM NaCl, then 
ligating with T4 DNA Ligase (400 U, New England Biolabs) at 16 ºC overnight 
in a buffer containing 50 mM NaCl, 10 mM Tris-HCl (pH 7.9) and 1 mM 
dithiothreitol.  The plasmids were then linearized with XmnI (New England 
Biolabs), allowing detection of the replication fork junction relative to the DNA 
ends, and measurement of the asymmetrically-generated long linear 
segments of the plasmid, to occur (Figure 4.1). 
Electron Microscopy 
Replication fork template DNA was diluted to 1 µg/ml in 10 mM HEPES 
pH 7.5, 0.1 mM EDTA and prepared for EM visualization as previously 
described (158).  An FEI Tecnai 12 instrument was used at 40 kV to 
photograph images on plate film or a Gatan US4000SP Ultrascan camera.  
Micrographs for publication were captured from plate film negatives using an 
Imacon Flextight 848 scanner.  Molecule lengths (in nm) were measured from 
Gatan digital images using Gatan Digital Micrograph software and  
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Figure 4.1. Schematic representation of replication fork templates. 
Details of the synthesis steps are in Materials and Methods.  The telomeric 
replication fork template was constructed on the plasmid pRST5NICK, and 
the CTG repeat template was made using the pCTG60NICK plasmid.  The 
lengths of the long linear segments of the plasmid are indicated in both the 
non-regressed and fully regressed forms of molecules containing only a single 
ds tail.  Patterned region indicates repetitive DNA.  Positions of the nicking 
site, the site of replication stalling, and the XmnI restriction site used to 
linearized the plasmid DNA are shown in the center panel of each template 
diagram. 
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converted to bp. 
The mean and standard deviation of the total DNA length (nm) of all 
measured molecules was determined, per experiment, and only molecules 
falling within the range: mean ± standard deviation, were used to determine 
percent of molecules regressed or non-regressed. 
 
RESULTS 
Synthesis of replication fork templates 
Synthetic model replication forks were prepared by nicking the repeat-
containing plasmids pRST5NICK and p(CTG)60NICK adjacent to the repeat 
tract and replicating in the absence of one of the four nucleotides.  Replication 
through the repeats stalled at the end of the tract, generating a ss tail that was 
converted to a ds tail by annealing and ligating complementary oligos along 
the length of the displaced strand.  In both cases, the positions of the nicking 
sites and sites of replication fork stalling were sufficiently close to (within 2-4 
bp of) the repeat tract that there was very little non-repeat DNA present in the 
ss tail and most of the displaced ss DNA could be converted to ds DNA by 
ligating complementary oligos.  The plasmids were then linearized so that the 
position of the replication fork junction relative to this restriction site could be 
determined by measuring the length of each of the longest segments of the 
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replication fork template from the DNA end up to the fork junction (Figure 4.1). 
Visualization of replication fork templates 
Visualization of the replication fork molecules containing telomeric or 
CTG repeat tracts revealed an array of DNA configurations (Figure 4.2).  For 
both model DNAs the most common species consisted of a linear replication 
fork template (Figure 4.2A, C, E, G) containing a single ds tail.  Also present 
were molecules containing two shorter ds tails (shown at higher magnification 
in Figure 4.2B, D, F, and H).  These are typical of chickenfoot intermediates 
generated by fork regression as seen by EM (198).  Six separate preparations 
of telomeric DNAs and three separate preparations of the CTG triplet repeat 
template were scored, with more than 200 molecules counted per experiment.  
On average, 32 ± 10% of all telomere model DNAs contained a chickenfoot 
structure within the repeat tract while 15 ± 7% of the CTG repeat containing 
DNAs contained such structures (Figure 4.3).  The substantial presence of 
these four-way junctions is highly significant,  since these structures were 
absent in similar preparations of non-repeat containing replication fork 
templates synthesized under the same conditions and prepared for EM using 
the identical protocol (198). Thus the appearance of these chickenfoot 
structures must reflect the result of spontaneous fork migration caused by 
features unique to repetitive DNA. 
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Figure 4.2 Visualization of DNA configurations by EM.   
Model replication forks were prepared for EM by mounting on carbon coated 
EM grids, and rotary shadowcasting with tungsten (Materials and Methods).  
Examples of linear molecules seen include replication fork templates 
comprising telomeric (A, B, C, D) or CTG (E, F, G, H) repeats, and containing 
only a single ds tail (A, C, E, G) or two shorter ds tails (B, D, F, H). Images 
shown in reverse contrast.  Bar is equivalent to 150 bp in panels showing full-
length molecules. 
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Figure 4.3. Graph of spontaneous regression of replication forks in vitro.  
All tailed molecules were counted and measured, per experiment, and the 
average fraction of these molecules that were determined to have regressed 
was calculated (lane 1).  Previously-reported values for regression of non-
repeat DNA (198) to allow for comparison to the repeat DNA results.  The 
average fraction of chickenfoot structures visualized by EM was also graphed 
as a percentage of all tailed molecules seen (lane 2). 
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Spontaneous replication fork regression in repetitive DNAs 
Template DNAs were linearized so that the repeat block measured 
from 28% to 45% (telomere repeat) or 38% to 44% (CTG repeat) of the total 
DNA length from the nearest end, providing a means to uniquely determine 
the position of the replication fork (Figure 4.1).  Molecules containing a single 
ds tail were photographed, and a minimum of 75 molecules for each template 
were analyzed to determine the position of the replication fork junction (see 
“Materials and Methods”).  This was necessary because molecules containing 
a single ds tail could represent one of three types of replication fork templates 
– unregressed; fully regressed; or partially regressed chickenfoot molecules in 
which one of the ds tails was too short to be visualized by EM (Figure 4.2H, 
arrow).  This was particularly important in the case of the CTG template, 
where the repeat tract was relatively short and the likelihood was high that 
one of the two ds tails of the chickenfoot intermediate would go unobserved.   
Telomeric forks were considered to have begun regressing when the 
longer segment of the plasmid was greater than 1928 bp plus one standard 
deviation of the mean total DNA length, per experiment.  Similarly the CTG 
repeat forks were considered to have begun regressing when the shorter 
segment of the plasmid was greater than 1322 bp plus one standard deviation 
of the mean total DNA length, per experiment.  On the average, 60 ± 8% of 
telomeric replication forks and 55 ± 12% of CTG repeat forks had regressed 
to some degree (Figure 4.3).   
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Previously, when replication fork molecules which lacked any repetitive 
sequences  at or near the fork and which contained only a single ds tail were 
examined, only 19% of all molecules were found where measurement of the 
long linear segments indicated that the replication fork had begun to regress 
(198).  Spontaneous replication fork regression in repetitive DNA was 
therefore determined to be 41% and 36% higher in telomeric and CTG repeat 
DNA, respectively, than in non-repeat DNA.  These results suggest that there 
is a high propensity for a paused replication fork to spontaneously regress 
when moving through repetitive DNA, resulting in a chickenfoot intermediate 
that would present a significant block to replication, requiring the action of 
recombination proteins to restart replication. 
 
DISCUSSION 
In this study we used EM to visualize stalled replication forks 
containing long runs of repetitive DNA sequences.  We have shown that these 
forks have a much greater tendency to spontaneously regress, resulting in 
four-stranded chickenfoot intermediates, than non-repeat containing DNA.  
Specifically, 60% of telomeric and 55% of CTG repeat forks had regressed to 
some degree, in contrast to 19% regression seen in non-repeat DNA.  Of 
particular interest were the greatly increased fractions of chickenfoot 
molecules seen in the repeat-containing DNAs: 32% of the telomeric 
templates and 15% of the CTG repeat templates were in 4-stranded 
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chickenfoot forms.  In contrast, our previous study of non-repeat containing 
forms revealed that these 4-stranded intermediates were absent unless p53 
was present to trap them (198).   
The accumulation of chickenfoot structures is intriguing, given that 
four-way junctions have a higher number of broken base pairs and are likely 
less energetically favorable than three-way junctions.  A possible explanation 
may be that chickenfoot structures carrying repetitive runs may be stabilized 
by additional secondary structures or repeat slippages in each of the repeat-
containing DNA arms.  However, we did not see any T- or Y-shaped 
protrusions in the slipped DNA arms, arguing that if they are present, they are 
not large.  These DNAs seem inherently more “slippery” than non repeat-
containing DNA, such that the replication forks are able to more easily 
transition back and forth between non-regressed and fully regressed states.  
During replication, repeat-containing DNA could therefore spend a 
significantly larger fraction of time in the partially-regressed state than other 
DNAs, and this could possibly account for the large percentage of chickenfoot 
structures seen.  This model assumes that fork regression would be equal, 
regardless of the orientation of the repeats.  However, since our studies 
concentrated on just one orientation for both repeats studied, we cannot rule 
out the possibility of orientation dependence on replication fork regression in 
these DNAs. 
This study has thus revealed a new feature of repetitive DNA that 
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could present a significant barrier to replication.  Furthermore, we believe that 
the four-stranded chickenfoot structures could present a significant problem to 
the cell, resulting in recruitment of unwanted recombination factors or leading 
to deleterious recombination events if repaired.  We have shown in our 
laboratory that p53 will bind to chickenfoot structures with great affinity (198) 
and it greatly increases the rate of Holliday junction cleavage by resolvase 
enzymes (200) in vitro.  Recently, similar results have been shown for the 
homologous recombination DNA repair protein XRCC3 in complex with 
Rad51C (S. Compton, unpublished data).  Thus, an abundance of chickenfoot 
structures in the cell may have significant downstream consequences for 
cellular signaling and DNA repair. 
Although the number of chickenfoot structures present in CTG repeat-
containing DNA was approximately half of that seen in the telomeric samples, 
we believe that this number would have been higher if the repeat tract in the 
plasmid was longer.  From measurements of the long linear segments of the 
plasmids, it was determined that approximately the same number of 
molecules had regressed to some degree in the telomeric samples as in the 
CTG-repeat samples.  The triplet repeat DNA therefore appears to be as 
slippery as the telomeric DNA.  Thus it seems probable that a large 
percentage of the chickenfoot molecules in the CTG-repeat samples 
contained one ds tail that was too short to be visualized by EM (Figure 4.2H, 
arrow).  Also, we found that annealing of the oligos along the ss tail to make 
the ds tail in these samples was somewhat inefficient, resulting in 
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replication fork templates containing a ds tail shorter than the expected 221 
bp.  Although the presence of ssDNA regions in the displaced tail may have 
had the ability to bind back to the template, resulting in replication forks with a 
loop at the fork junction, no evidence of these structures was seen.  More 
significantly, ssDNA regions resulting from poor oligo annealing did not seem 
to interfere with the ability of the replication forks to regress to a high degree, 
and binding back of the displaced ss tail to the template could not account for 
the chickenfoot structures seen. 
Because of the considerable instability of repeat tracts in bacteria, this 
study was limited to the telomeric repeat TTAGGG and the triplet repeat 
(CAG)n•(CTG)n.  However, in the future studies with replication fork templates 
containing sufficiently long stretches of the repeats (CGG)n•(CCG)n, 
(GAA)n•(TTC)n, (CCTG)n•(CAGG)n, (AATCT)n•(AGATT)n and 
(C4GC4GCG)n•(CGCG4CG4)n will be important to extend and generalize these 
observations to all of the known disease-related repeats.   
Our observations are therefore consistent with repetitive DNA being a 
poor substrate for replication in vitro (192,196,201,202).  The existence of 
stable four-stranded chickenfoot structures may explain the need for 
additional helicases such as BLM and WRN for efficient replication through 
telomeres in vivo (93,94,102,103,116).  The data also favor a model for 
expansion of disease-related repeats that involves replication restart via 
chickenfoot intermediates, particularly in human cells where the repeat 
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blocks can be much longer than those investigated in the bacterial model 
study (131).  
Interestingly, whereas replication of telomeric DNA tends to stall in vitro 
((196) and unpublished data) and the G-rich strand may form G-quartets in 
vivo (203), human telomeres are replicated as rapidly as bulk DNA 
(100,204,205).  Our data therefore also raise the possibility that factors at the 
telomere are actively involved in recognizing regressed-fork chickenfoot 
structures and rapidly resolving them in a tightly regulated process to restart 
replication, without allowing significant changes to the length of the telomere.  
The recent report that the telomeric binding protein Taz1 is required for 
replication of telomeres in the fission yeast Schizosaccharomyces pombe 
(101) further suggests that factors such as the telomere binding proteins 
TRF1 or TRF2 might play such a role in human cells. 
CHAPTER 5: THE BASIC DOMAIN OF TRF2 DIRECTS BINDING TO DNA 
JUNCTIONS IRRESPECTIVE OF THE PRESENCE OF TTAGGG REPEATS 
 
INTRODUCTION 
Telomeres are nucleoprotein structures that protect the ends of 
chromosomes and are essential for regulating the replicative lifespan of 
somatic cells.  The DNA component of the mammalian telomere consists of 
long double-stranded (ds) tracts of the hexameric repeat unit TTAGGG (3) 
that ends with a G-rich 3′ single stranded (ss) overhang (2).  Telomeric DNA 
is thought to be organized into a t-loop “end-capping” structure by the 
telomere binding proteins TRF1, TRF2 and POT1 and the proteins that bind 
to them, TIN2, TPP1 and Rap1 (10,16).  This higher-order structure may 
enable cells to distinguish chromosome ends from random double-strand 
breaks.  Large blocks of telomere repeat sequences can be lost when these 
end-capping proteins are disrupted, or problems are encountered during DNA 
replication or repair (reviewed in (206). This typically results in p53- and Rb-
mediated senescence or cellular crisis, as evidenced by end-to-end fusions of 
chromosomes, ATM dependent activation of p53 and apoptosis (reviewed in 
(185). 
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Much has been learned about the properties of TRF1 and TRF2 
including their binding to DNA and the effects of their ablation or 
overexpression in the cell.  We observed that TRF1 forms filamentous 
structures on long tracts of telomeric DNA in vitro (162), whereas TRF2 binds 
preferentially to the telomeric DNA at the junction between the duplex repeats 
and the ss overhang (69).  Both TRF1 and TRF2 contain a similar Myb 
domain at their C-terminus that mediates their binding to ds telomeric DNA 
(207).  TRF1 and TRF2 differ in their N-termini however, which are rich in 
either acidic residues in TRF1, or basic residues in TRF2.  The function of the 
basic domain of TRF2 is poorly understood.  Deletion of this domain (TRF2∆B) 
does not impede the DNA binding activity of TRF2 or its localization to 
telomeres in vivo, but expression of TRF2∆B resulted in stochastic deletions of 
telomeric DNA, generation of t-loop-sized telomeric circles (t-circles), cell 
cycle arrest and induction of senescence in human cells (59,70).  In addition, 
recent evidence suggested that the basic domain, but not the Myb domain, 
was required for TRF2 association with photo-induced double strand breaks 
in non-telomeric DNA in human fibroblasts (208).  
Relatively little is known about the replication of mammalian telomeric 
DNA in vivo, however experiments in ciliates and budding yeast have 
provided insight into how this occurs in other eukaryotes.  During each round 
of replication, all but the very end of the telomere is replicated by the 
conventional semi conservative polymerase machinery (95).  Leading strand 
sequences eroded in the last round of replication (end replication problem) 
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can be restored by the reverse transcriptase telomerase (29), while the 
lagging strand is concurrently elongated by polymerases α and δ using the 
newly formed G strand as the template (30). 
A possible complication of replication at the telomere is the 
requirement for protecting the DNA ends from recognition by DNA repair 
factors, while still allowing the DNA to be accessible to the replication 
machinery.  Also, replication of telomeric DNA tends to stall in vitro (196) and 
long blocks of telomeric repeats are highly unstable when transformed into E. 
coli cells that lack recombination enzymes, suggesting difficulties with DNA 
replication through the telomeric tract (unpublished data).  Furthermore, the 
G-rich strand of telomeric DNA has the tendency to form G-quartets (97) and 
the complementary cytosine-rich strand can fold into an intercalated tetramer 
called the i-motif (98).   
The fact that human telomeres are replicated as rapidly as the bulk 
DNA (100) suggests that in addition to the standard replicative machinery, 
telomere-targeted factors may exist to actively facilitate its rapid replication.  
Direct evidence for the requirement of such telomeric factors at the replication 
fork was recently discovered in the fission yeast Schizosaccharomyces 
pombe, where the telomere binding protein Taz1 is required for efficient 
replication of telomeres (101).  Also, in addition to the normal replicative 
helicases present at forks, the RecQ helicases WRN and BLM, implicated in 
premature ageing diseases, have been shown to be important for proper 
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telomere replication and maintenance in human cells (94,102,103).   
The RecQ helicases have been shown to unwind G quartets (107) and 
promote branch migration of 4-stranded junctions similar to chickenfoot 
structures (108,109).  In human cells, TRF2 co-localizes and physically 
interacts with WRN (134), and it binds to and stimulates the activities of both 
the WRN and BLM helicases in vitro (105).  TRF1 and POT1 have also been 
shown to regulate WRN and BLM unwinding of telomeric substrates in vitro 
(110,133).  Furthermore, in vitro, overexpression of TRF1 and TRF2 led 
directly to replication fork stalling (196), suggesting that the telomere binding 
factors also have a direct effect on the replication machinery.   
We recently discovered a new feature of telomeric DNA that may 
explain this requirement for the RecQ helicases during telomere replication.  
Using EM and model replication fork templates that mimic a replication fork 
that had transited a long block of telomeric repeats, we discovered that 
telomeric DNA is inherently more slippery than non-repeat-containing DNA, 
such that the replication forks are able to more easily transition back and forth 
between non-regressed and fully regressed states (unpublished data).  During 
replication, repeat-containing DNA could therefore spend a significantly larger 
fraction of time in the partially-regressed state, characterized by a Holliday 
junction or “chickenfoot” structure, than other DNAs.  We believe that this 
presents a significant problem to the cell, where these 4-stranded structures 
could result in recruitment of unwanted recombination factors or lead to 
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deleterious recombination events if repaired.  p53 will also bind to stalled 
chickenfoot structures with great affinity, suggesting that it may have the 
ability to halt excessive fork regression (198).  These observations led us to 
ask whether one or both of the primary ds telomere binding proteins TRF1 
and TRF2 might also show some unusual binding with regards to 3- and 4-
way DNA junctions, when they occur within telomeric tracts.     
To test this hypothesis, we generated a set of DNA templates including 
telomeric and non-telomeric replication forks, Holliday junctions, and model 
telomeres containing 3′ overhangs.  Using EM and polyacrylamide gel-shift 
assays we evaluated binding to these templates by TRF1, TRF2 and TRF2∆B 
as well as a peptide encompassing the basic domain of TRF2 and another 
similar “mutant” peptide containing a rearrangement of four amino acids (aa).  
In this paper we show that TRF2, but not TRF1 nor TRF2∆B, is able to 
target the junctions of replication forks, chickenfoot structures and Holliday 
junctions.  Junction binding occurred irrespective of the presence of TTAGGG 
repeats, and a bias for 4-stranded junctions was detected.  The peptide 
mimicking the basic domain of TRF2 recapitulated this DNA-junction binding, 
whereas the mutant peptide could not.  Furthermore, in the absence of other 
telomere binding proteins, TRF2 lacking the basic domain was not able to 
target the end of the large model telomeres and facilitate t-loop formation in 
vitro.  We therefore suggest a novel role for the previously uncharacterized 
basic domain of TRF2, which is to facilitate TRF2 binding to 
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chickenfoot intermediates of telomere replication fork regression, presumably 
preventing their recognition by Holliday junction resolvases.  The data are 
also the first direct demonstration of TRF2 binding specifically and selectively 
to DNA junctions, irrespective of the presence of telomeric repeats. 
 
MATERIALS AND METHODS 
DNA probes and templates. 
[γ-32P]ATP end-labeled J12 4-way junction probes (200); large 
Holliday-junction DNA templates (HJ575; (209); model non-telomeric 
replication forks (198); and model telomere DNA (69) was synthesized as 
previously described.  A telomeric probe with a 14 nt overhang was prepared 
by annealing the [γ-32P]ATP end-labeled oligonucleotide (oligo) 5′-
CTAACCCTAACCCTGTCCTAGCAATGTAATCGTCTATGAGTCTG-3′ to the 
oligo 5′-
CAGACTCATAGACGATTACATTGCTAGGACAGGGTTAGGGTTAGGGTTA
GGGTTAGGG-3′.  A hairpin probe consisting of a 7 nt linker and a 21 bp stem 
was prepared by heating and step-wise cooling the [γ-32P]ATP end-labeled 
oligo 5′-
CTTATTCACAGACCACGACTCAAAAAAAGAGTCGTGGTCTGTGAATAAG-
3′.  All annealed products were purified on 10% non-denaturing 
polyacrylamide gels. 
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Telomeric replication forks were created using a variant of pRST5 (69) 
containing a nicking site directly adjacent to the telomeric repeat tract 
(unpublished data).  The plasmid was nicked with N.BbvC IA (New England 
Biolabs (NEB), Ipswich, MA) and then incubated with the Klenow fragment 
(exo-) of DNA polymerase 1 (NEB), and 0.5 mM of each of dTTP, dATP, 
dGTP to generate a ss tail by strand displacement of the repeat tract.  The ss 
tail was converted to a ds tail by annealing a 228-fold molar excess of the 
oligo 5′-CCCTAACCCTAACCCTAACCCTAA-3′ to the template for 30 min at 
37 ºC in 100 mM NaCl, and ligating with T4 DNA Ligase (400 U, NEB) at 16 
ºC overnight in 50 mM NaCl, 10 mM Tris-HCl (pH 7.9) and 1 mM dithiothreitol.  
When required, the replication templates were linearized with XmnI (NEB) for 
1 h at 37 ºC.  
Proteins and Peptides 
NH2-terminal [His]6-tagged human TRF1, TRF2 and TRF2
∆B were 
purified to homogeneity from baculovirus-infected insect cells by the method 
of Bianchi et al., except that a TalonTM Metal affinity resin (Clontech, Palo Alto, 
CA) was employed instead of Ni-NTA (210).  p53 as well as the carboxy-
terminal domain of the p53 protein, comprising amino acid residues 311 to 
393, were purified as previously described (211).   
Two peptides, each containing an NH2-terminal biotin motif, were 
synthesized by the UNC Micro-Protein Facility, UNC School of Medicine, 
Chapel Hill, NC (Figure 5.1B).  The first peptide (Peptide_B) consisted 
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of aa 2-31 of wild type human TRF2 (207), whereas the second peptide 
(Peptide_M) comprised a four aa sequence rearrangement of the first peptide. 
Electron Microscopy 
Binding assays of TRF2 and TRF2∆B to the model telomere were done 
as previously described (69).  Complexes of p53, TRF1, TRF2, TRF2∆B and 
both peptides with Holliday junction or replication fork DNA were formed by 
incubating a 25:1 molar ratio of protein monomer:DNA in a 20 µl volume of 
EM buffer (20 mM HEPES pH 7.5, 0.1 mM EDTA, 0.5 mM DTT, 75 mM KCl) 
for 20 min at room temperature.  A 5X molar excess of streptavidin (Molecular 
Probes, Eugene, OR) to peptide was added to samples containing biotin-
tagged peptide, for 5 min at room temperature. Samples were fixed with 0.6% 
(w/v) glutaraldehyde for 5 min at room temperature followed by filtration 
through 2 ml columns of 2% agarose beads (50-150 µ, Agarose Bead 
Technologies, Tampa, FL) pre-equilibrated with 0.01 M Tris-HCl (pH 7.6), 0.1 
mM EDTA.  The purified samples were prepared for EM by rotary 
shadowcasting with tungsten as previously described (158).  An FEI Tecnai 
12 electron microscope equipped with a Gatan 4K x 4K CCD camera were 
used to photograph images. 
Mobility shift assays 
Reaction mixtures (10 µl) containing probes (10 nM) and the proteins 
(see figure legends for details) were incubated at room temperature for 20 
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min in EM buffer.  The mixtures were adjusted to 10% glycerol and loaded on 
3.5% non-denaturing polyacrylamide gels in 45 mM Tris–borate, 1 mM EDTA. 
The gels were run at 140 V for 1 h at 4°C, dried, analyzed by autoradiography 
and quantified using a Storm 840 phosphorimager (Molecular Dynamics). 
Calculating Kd 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA) was used 
for non-linear regression of the data obtained from the mobility shift assays.  
The one site hyperbolic binding equation used was: % Probe Shifted = (Bmax x 
[nM Protein])/([n MProtein] + Kd).  In experiments with the Holliday junction 
probe, dissociation constant (Kd) values were converted to association 
constant (Ka) values: Ka = 1/Kd; then multiplied by the EM specific binding 
factor (see Results): Ka, apparent = Ka x (% EM junction binding); and again 
converted to a dissociation constant: Kd, apparent = 1/Ka, apparent (nM). 
 
RESULTS 
TRF2, but not TRF1, binds to DNA Junctions in vitro. 
To examine the binding of TRF1 and TRF2 to replication forks and 
Holliday junctions, and to compare this with previous studies of p53 (198), a 
series of large model templates were constructed for EM.  Previously we 
described the generation of a model replication fork consisting of a ~500 bp 
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arm extended from a 3 kb linear or circular DNA at a unique site which is at 
the end of a 500 bp cassette consisting of a random but G-less sequence 
(198). We constructed a new replication fork template based on this design 
from a plasmid containing a 560 base pair (bp) telomeric cassette (Figure 
5.1A).  In this DNA, two arms of the Y-fork molecule contain telomere repeats 
leading up to the fork junction.  In addition, a Holliday junction template 
containing 500 bp arms of plasmid-derived DNA extended from the well 
known J12 junction was prepared as previously described (200).   
Purified TRF1 and TRF2 were incubated with the template DNAs and 
prepared for EM.  EM binding experiments were conducted in parallel with 
purified p53.  Examination of fields of molecules from incubations of TRF2 
with the model telomere replication fork revealed several DNA-protein 
configurations.  When a 25:1 molar ratio of TRF2 monomers to DNA template 
was used, approximately one third of all molecules contained a particle of 
TRF2 bound at the center of the stalled fork junction (Figure 5.2A). Of these 
molecules, a subset of the forks had regressed, generating chickenfoot 
structures, and TRF2 was also observed bound at these junctions (insert, 
Figure 5.2A).  The remainder of the DNA consisted of DNA templates with no 
protein bound (the majority), a fewer number of DNAs containing TRF2 
protein bound elsewhere on the DNA template but not at the fork junction, and 
more frequently, aggregates of two or more DNAs bound by a large mass of  
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Figure 5.1: DNA, protein and peptide constructs used in this study. 
(A). Telomeric replication fork template and chickenfoot structure, patterned 
region indicates TTAGGG repeats.  (B). TRF1 and TRF2 have similar TRFH 
dimerization and Myb domains.  TRF2 has a unique N-terminal basic domain 
(B, aa 13-30) with conserved residues (indicated by a *).  TRF2∆B is a deletion 
mutant of TRF2 lacking the first 44 aa.  The basic (Peptide_B) and mutant 
(Peptide_M) peptides have an N-terminal biotin moeity (bt), and they differ in 
their sequences (grey lettering) by a re-arrangement of four aa (black 
lettering). 
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Figure 5.2: TRF2 binds DNA junctions in vitro.  
(A, C). Discrete complexes of TRF2 bound to the junctions of the 3-stranded 
replication forks and the 4-stranded chickenfoot structures (arrow, insert); (A, 
telomeric template; C, non-telomeric template).  (B). Extensive, filamentous 
binding of TRF1 to a model telomeric replication forks.  (D). TRF2 bound to 
the center of Holliday junction template DNAs.  Bar is equivalent to 450 bp in 
panels showing full-length molecules. 
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TRF2 (data not shown).  These aggregates became more abundant in binding 
preparations containing molar ratios of TRF2 monomers to DNA template 
greater than 25:1.  Of the TRF2-bound molecules where TRF2 was not 
located at the fork junction, the majority had TRF2 bound sufficiently close to 
the fork that we presumed it was bound along the TTAGGG tracts.  
Quantification of the results from scoring hundreds of molecules is described 
below.  While the TRF2 particles varied in size, in most cases the size range 
was much less variable when bound to the center of the 3-way or 4-way 
junction than in the instances when TRF2 was observed bound along the 
duplex TTAGGG tracts (Figure 5.2A, insert) and the particle size was 
suggestive of TRF2 dimers or tetramers.  When parallel experiments were 
performed with TRF1, long arrays of bound TRF1 were seen localized along 
the telomeric repeats (Figure 5.2B) resembling the TRF1 filaments formed 
along duplex TTAGGG tracts as previously described (162). 
For comparison, TRF1 and TRF2 were incubated with the random 
sequence replication fork template lacking TTAGGG repeats.  The binding of 
TRF1 to this template was low (quantified below), as expected from the lack 
of telomeric repeats.  Of great interest however was the observation that 
incubation of TRF2 with this template led to discrete TRF2 complexes at the 
3-way or 4-way junctions (Figure 5.2C).  In molecules in which the forks had 
regressed into 4-way chickenfoot forms, TRF2 complexes were more 
frequently observed bound to the DNA and almost always at the 4-way 
junction (insert, Figure 5.2C and quantified below).  This led us to 
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examine TRF2 binding to Holliday junction DNA containing 500 bp arms 
(Figure 5.2D).  Indeed, by EM we found that TRF2 bound well to these 
structures, localizing to the center of the 4-way junction.  By comparison, 
TRF1 bound poorly to these structures, and when it did, the binding appeared 
to be random with only a small percent of bound TRF1 found at the center of 
the template. 
Quantification of TRF1 and TRF2 binding to 3-way and 4-way junctions: 
comparison with p53 binding. 
We previously examined the binding of p53 to random sequence 
replication fork templates (198) as well as to large Holliday junction templates 
(200).  We were thus able to combine these results in a comparison of TRF1 
and TRF2 binding to these templates (Figure 5.3A, B and C).  An average of 
179 molecules over three experiments was counted per experimental 
condition.   
Incubation of p53 (25:1) with the telomeric replication fork template resulted in 
observation of p53 at the fork and the frequency (69 ± 3% versus 8 ± 1% 
elsewhere on the DNA, Figure 5.3A) was comparable to previous 
observations with non-telomeric forks (56% at the fork versus 15% bound 
elsewhere; (198).  We could not assess TRF1 binding to telomeric replication 
fork templates because of its extensive binding to the telomeric tract.  Also, 
since the number of DNA molecules contained within the TRF2 aggregates 
could not be determined by EM, they were not included in the total 
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number of DNAs counted.  Thus, the actual level of TRF2 binding to the 
telomeric replication fork is likely to be higher than the value cited here (34 ± 
21% versus 6 ± 2% elsewhere on the DNA, Figure 5.3A) since the values 
were calculated as the percentage of the individual (non-aggregated) DNAs 
only. The relatively wide spread in calculated TRF2 binding is most likely due 
to a variation in the abundance of TRF2 aggregates in these samples, 
because when TRF2 binding in these samples was evaluated as a 
percentage of individually bound molecules, the standard deviation was small 
(76 ± 5% bound at the junction versus 24 ± 5% bound elsewhere).    
A more pronounced preference for the DNA junction was revealed for 
TRF2 binding to non-telomeric replication forks, where protein-DNA 
aggregates were less abundant, and TRF2 bound to the fork junction 48 ± 6% 
of the time, and elsewhere on the DNA only 5 ± 3% of the time.  This was in 
contrast to TRF1 binding to the non-telomeric replication forks, which was low 
and seemingly random; only 6 ± 1% of molecules had TRF1 bound at the fork 
junction, whereas 13 ± 5% had TRF1 bound somewhere else on the DNA. 
TRF2 bound even more strongly to the Holliday junction templates, 
targeting the center of the 4-way junctions 75 ± 5% of the time and binding 
elsewhere on the DNA only 8 ± 4% of the time (Figure 5.3B).  Previously, 
when p53 binding to Holliday junctions was studied by EM, 59% of all 
molecules were bound at their center by p53 (200).  When TRF1 binding to 
the Holliday junction templates was examined, we found that it bound 
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Figure 5.3: TRF2 junction binding is biased towards 4-way junctions.   
(A). Binding of p53, TRF2 and TRF1 to the telomeric replication fork 
templates (tel. RF) and the non-telomeric replication fork templates (non-tel. 
RF) was visualized by EM and quantified.  Percentages are calculated as a 
fraction of all replication forks counted (3-way and 4-way junctions combined).  
Only molecules with protein bound at the junction of the replication fork or 
chickenfoot structure were considered junction-bound molecules. Data are 
represented as mean ± SD.  (B). Holliday junction (HJ) templates bound by 
TRF1 or TRF2 were similarly quantified. (C). Percentages of TRF2 and p53 
binding to replication forks are calculated as a fraction of molecules with the 
same shape.  (D).  Mobility shift assay of the [γ-32P]-labeled J12 junction 
probe alone (lane 1) or bound by p53 (at a molar ratio of 30:1 protein:probe, 
lane 2); TRF2 (25:1, lane 3; 50:1, lane 4); an 82 aa C-terminal fragment of 
p53 containing the basic domain (81:1, lane 5); and TRF1 (50:1, lane 6; 
101:1, lane 7). 
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considerably less well (18 ± 6% bound at the junction) than TRF2, and that 
most binding occurred on one or more of the arms of the Holliday junction, 
rather than at the DNA junction (27 ± 5%).  When binding to non-telomeric 
replication forks was examined in more detail it became apparent that TRF2 
has a greater affinity for the 4-stranded replication fork structures (Figure 
5.3C).  Specifically, we considered TRF2 binding to the Y-shaped 3-way 
junctions as a fraction of all 3-stranded junctions and similarly, TRF2 binding 
to the chickenfoot 4-way junctions as a fraction of all 4-way junctions.  A clear 
bias was observed, where TRF2 bound to 89 ± 4% of all 4-way junctions 
versus 36 ± 11% of all 3-way junctions.  When the DNA template contained 
telomeric repeats, this preference was not as strong (42 ± 3% of all 4-way 
junctions versus 13 ± 4% of all 3-way junctions), suggesting that the 
sequence-specific binding of TRF2 to the surrounding sequences led to the 
apparent lower fractional localization to the fork.  p53 showed a slight bias for 
chickenfoot structures when bound to the telomeric replication fork (82 ± 1% 
of all 4-way junctions versus 59 ± 10% of all 3-way junctions) and no bias 
when binding to non-telomeric replication forks (approximately 52 ± 8% of all 
4-way junctions versus 52 ± 7% of all 3-way junctions; (198).  These data 
suggest, therefore, that TRF2 has a considerable and specific binding affinity 
for DNA junctions, with a bias for 4-stranded DNA junctions resembling 
Holliday junctions. 
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Mobility shift analysis of TRF1 and TRF2 binding to 3- and 4- armed DNA 
templates. 
To further examine the binding of these proteins to fork junctions, 
mobility shift assays were carried out using TRF2, TRF1, p53 and the 82 aa 
C-terminal fragment of p53 with a 100 bp [γ-32P] end-labeled Holliday junction 
probe (Figure 5.3D).  TRF2 shifted the Holliday junction probe equally as well 
as p53, confirming our EM results.  In contrast, much higher levels of TRF1 
were required to observe any shift of the probe suggesting that this interaction 
with the probe is non-specific for the DNA strands (as was visualized by EM).  
As a control, we duplicated these binding assays with a small [γ-32P] end-
labeled hairpin probe, and in this case neither TRF1 nor TRF2 were able to 
bind to and shift the probe (data not shown). 
The TRF2 basic domain targets DNA junctions in vitro. 
These results suggest that TRF2 and p53 share common features in 
binding to 3-way and in particular 4-way junctions in a non-sequence-specific 
manner. This activity resides in the C-terminal basic domain of p53.  To 
determine if the basic domain of TRF2 is involved in targeting TRF2 to DNA 
junctions, we purified an NH2-terminal deletion mutant of TRF2 lacking the 
TRF2-specific basic domain (TRF2∆B, Figure 5.1B).  We also had a peptide 
synthesized (Peptide_B, Figure 5.1B) which consists of the amino acid 
sequence from aa 2-31 of TRF2, and thus encompasses the basic domain 
(aa 13-31) of TRF2.  In addition, we had a “mutant” peptide synthesized 
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(Peptide_M, Figure 5.1B) comprised of the same number and composition of 
amino acids as Peptide_B, such that the overall positive charge of both 
peptides was the same, but containing a rearrangement of four amino acids, 
two of which are conserved among the species Gallus gallus (Chicken), 
Muntiacus reevesi (Chinese muntjak), Muntiacus muntjak vaginalis (Muntjak), 
Mus musculus (Mouse) and Homo sapiens (Human) (Homologous vertebrate 
genes database, HOVERGEN). 
EM binding experiments were conducted with these proteins using the 
same conditions as used for TRF2 and TRF1, except that streptavidin was 
added to each of the peptide-containing samples just prior to sample 
preparation for EM.  Both peptides contained an NH2-terminal biotin moeity to 
which streptavidin could bind, thereby increasing the overall molecular weight 
of the peptides from 3 kDa to 56 kDa (equivalent to a monomer of TRF2 of 55 
kDa) and allowing them to be visualized by EM. 
In experiments examining TRF2∆B binding to telomeric replication fork 
templates, the large majority of molecules consisted of aggregates of two or 
more DNAs bound by a large mass of TRF2∆B protein, although in some 
cases individual molecules of DNA could be seen.  Frequently, these 
individual DNAs contained long arrays or masses of bound TRF2∆B, although 
less often we were able to visualize a discrete particle of TRF2∆B bound to the 
DNA (Figure 5.4A).  In such instances, TRF2∆B was localized to the telomeric 
repeats (on the displaced strand or within a distance equivalent to 500 
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bp from the fork junction) but it was rarely observed bound to the replication 
fork junction.  Because most of the TRF2∆B protein in the sample was 
contained within the aggregates of TRF2∆B, we were not able to quantify 
TRF2∆B binding to this template DNA.  Also, we did not separately quantify 
binding of the peptides to the telomeric replication fork templates.  The 
peptides do not have a telomere-repeat recognition motif and were observed 
to have similar binding to these templates (Figure 5.4B) as to the non-
telomeric replication fork templates (Figure 5.4C). 
As with TRF2, in experiments containing Peptide_B and the non-
telomeric replication fork template, 41 ± 1% of all molecules consisted of a 
complex of streptavidin and Peptide_B bound at the center of the stalled fork 
junction (Figure 5.4C, non-telomeric replication fork with insert showing 
chickenfoot structure; see also Figure 5.5A).  Protein bound elsewhere on the 
DNA templates 8 ± 1% of the time.  No protein-bound complexes were seen 
in samples containing DNA and streptavidin alone (data not shown).  
Intriguingly, the mutant Peptide_M displayed 30 ± 5 % and 35 ± 6% binding to 
the junction and DNA arms of the non-telomeric replication forks, respectively.  
This reflects an increase in the overall binding from 49% (Peptide_B) to 65% 
(Peptide_M), with a seemingly small difference in junction binding (41% 
versus 30% respectively) between the two peptides.  However, when we 
examined the junction binding in more detail, we noticed that the mutant 
Peptide_M had significantly decreased binding to 4-way junctions, with  
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Figure 5.4: The TRF2 basic terminus binds DNA junctions in vitro 
whereas TRF2∆B protein does not. 
(A). TRF2∆B bound to the TTAGGG repeats of the telomeric replication fork 
template.  (B, C, D). Discrete molecules of streptavidin-bound Peptide_B at 
the junctions of the telomeric chickenfoot structure (CFS, A); the non-
telomeric replication fork (C) or CFS (arrow, insert); and the Holliday junction 
template DNAs (D).  Bar is equivalent to 450 bp in panels showing full-length 
molecules. 
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little change in binding to 3-way junctions.  Specifically, when Peptide_B-
bound molecules were evaluated as a fraction of the total DNA molecules with 
the same shape, Peptide_B bound to 94 ± 9% of all 4-stranded replication 
fork junctions versus 32 ± 8% of all 3-stranded junctions.  In contrast, 
Peptide_M bound to only 33 ± 0% 4-stranded junctions (a reduction in binding 
of 61%) whereas it was still able to bind to 29 ± 6% of the 3-stranded 
junctions (a reduction in binding of only 3%).  Therefore, it appears that a 
rearrangement of two conserved amino acids with two non-conserved amino 
acids specifically disrupted 4-way junction binding of the peptide mimicking 
the TRF2 basic domain, even though overall (non-specific) binding increased, 
and binding to the 3-way junctions remained largely the same.  
The TRF2 truncation mutant, TRF2∆B, showed only 7 ± 6% binding to 
the non-telomeric replication fork junctions, preferring to bind somewhere else 
on the template 26 ± 6% of the time.  Therefore it seems that the loss of the 
basic domain in the truncated TRF2 construct greatly attenuated its ability to 
target replication fork junctions, where junction-binding was reduced from 
48% to 7%, and non-junction binding was increased from 5% to 26% 
(compare Figures 5.2A and 5.5A).  These results were even more 
pronounced in EM experiments done with the Holliday junction template 
(Figure 5.4D).  Junction binding for the Peptide_B, Peptide_M and TRF2∆B 
constructs was 60 ± 11%, 6 ± 4% and 16 ± 6% respectively, and non-junction 
binding was 3 ± 1%, 22 ± 3% and 12 ± 6% respectively (Figure 5.5A).   
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Figure 5.5: The basic domain of TRF2 is required for binding to 4-way 
junctions. 
(A). Binding of the TRF2 basic peptide (Peptide_B), the mutant peptide 
(Peptide_M) and the TRF2 truncation mutant TRF2∆B to the non-telomeric 
replication fork templates (non-tel. RF) and the Holliday junction templates 
(HJ) was visualized by EM and quantified.  Percentages are calculated as a 
fraction of all molecules counted.  Only molecules with protein bound at the 
replication fork junction or at the center of the four strands of the Holliday 
junction were considered junction-bound molecules. Data are represented as 
mean ± SD.  (B, C). Mobility shift assays of the [γ-32P]-labeled J12 junction 
probe alone (lanes 1) or bound by the basic peptide (B, lanes 2-4); the mutant 
peptide (B, lanes 5-7); TRF2 (C, lanes 1-8) and TRF2∆B (C, lanes 9-14).  
Increasing peptide:probe molar ratios used were 1:1, 5:1 and 10:1, with each 
sample containing a 5:1 molar ratio of streptavidin protein:peptide. (D). 
Apparent dissociation constants (Kd) for TRF2, TRF1, TRF2∆B, the basic 
peptide (Pep_B) and the mutant peptide (Pep_M) binding to the [γ-32P] end-
labeled Holliday junction probe (J12) or the small [γ-32P] end-labeled telomere 
probe.
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Thus, TRF2 binding to the center of Holliday junction templates was reduced 
by 59% (from 75%) when the basic region was absent, and Peptide_B binding 
was reduced by 56% (from 60%) in the mutant Peptide_M samples.  All of 
these data suggest, therefore, that the junction-binding activity (specifically 
the 4-way junction-binding activity) of TRF2 is mediated by the NH2-terminal 
amino acids containing the basic domain. 
Junction-binding evaluated using an apparent dissociation constant. 
To compare the proteins used in this study with respect to Holliday 
junction binding, mobility shift assays were performed using a constant 
amount (10 nM) of the small Holliday junction probe in each sample.  The 
concentration was varied for each protein, in increasing increments, until no 
more probe could be shifted into the gel.  Two examples of these experiments 
are shown in Figures 5.5B and C.  All experiments were performed a 
minimum of three times and averages were taken for each data point.  
Binding isotherms were generated with % probe shifted (y-axis) as a function 
of protein concentration (x-axis).  In all instances, non-linear regression of the 
data using a one site hyperbolic binding equation gave a goodness of fit (R2) 
≥ 0.9. The apparent Kd values obtained were therefore: TRF2 (614 nM), 
TRF1 (819 nM), TRF2∆B (1401 nM), Peptide_B (261 nM) and Peptide_M 
(1065 nM).  However, because gel-shift analysis does not distinguish junction 
binding from non-specific ds DNA binding, we adjusted the apparent Kd 
values we obtained by the following “specific binding factors” 
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(corresponding to the % junction-specific binding observed for each protein 
via EM): TRF2 (93%), TRF1 (39%), TRF2∆B (57%), Peptide_B (95%) and 
Peptide_M (21%).  The resultant “apparent Kd” values (Figure 5.5D) clearly 
highlight the strong junction binding of TRF2 (661 nM) and the basic domain 
peptide (275 nM) versus the weaker, more random binding of TRF1 (2100 
nM), TRF2∆B (2458 nM) and the mutant peptide (5071 nM).  Interestingly, the 
apparent Kd values for TRF1 and TRF2∆B are very similar.  This result is not 
surprising considering that both of these proteins have very similar Myb DNA 
binding domains that would likely bind to non-telomeric DNA with a similar 
low-level affinity.   
To test the activity of the telomere-binding proteins under the binding 
conditions used, the mobility shift binding assays and non-linear regressions 
of the data were duplicated using a small [γ-32P] end-labeled telomeric probe.  
In all cases, the one site binding hyperbola again gave a decent fit (R2 ≥ 0.91).  
Binding of all three proteins to the telomeric probe appeared to be equally as 
good, with TRF1 binding the strongest (Figure 5.5D).  Most interestingly, 
TRF2 and TRF2∆B had an almost identical affinity for the telomere probe, 
suggesting that deletion of the basic domain had not destabilized the TRF2 
core structure.  Therefore, the lower junction binding seen in the TRF2∆B 
constructs were not a result of destabilization of the Myb DNA-binding 
domain.  Moreover, under the experimental conditions used TRF2 appeared 
to have a slightly smaller Kd when binding to the Holliday junction probe than 
to the telomeric probe, suggesting that the basic domain of TRF2 has a 
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similar, if not greater, affinity for DNA 4-way junctions as the Myb domain has 
for the consensus telomeric sequence.  The same mobility shift assays were 
also performed with streptavidin binding to the Holliday junction probe, as well 
as all proteins binding to a small single-stranded DNA probe.  In both cases, 
none of the probe was shifted in the gels, indicating the absence of binding 
(data not shown).  
TRF2∆B exhibits diminished targeting of the ds/ss telomere overhang 
junction. 
Large model telomeres were constructed from a 3.5 kb telomere-
repeat containing vector such that 560 bp of telomeric repeats were 
positioned at the end of the linearized DNA.  A 54 nt overhang was ligated 
onto the end containing the telomere repeats, while the opposite end was 
kept blunt.  TRF2 and TRF2∆B were simultaneously incubated with the DNA 
and prepared for EM (69).   
TRF2 and TRF2∆B appeared to have the same activity and overall 
affinity for the model telomeres, binding (at all positions) 73 ± 11% (TRF2) 
and 70 ± 12% (TRF2∆B) of the time, respectively.  However, we noticed a 
difference in the position of each of these proteins on the model telomere 
template.  In experiments containing TRF2, when we considered protein-
bound molecules, 50 ± 10% consisted of a particle of TRF2 bound at the end 
of the model telomere (Figure 5.6A, Figure 5.7) and 34 ± 6% had TRF2 bound 
within 560 bp of the end of model telomere (presumably within the 
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telomeric repeats).   Also observed were molecules where it appeared that 
the ss overhang had invaded the duplex repeat to form a t-loop, with 15 ± 2% 
bound by a molecule of TRF2 at the junction of the invasion site (Figure 5.6B 
and C).  TRF2∆B bound to the end of the model telomere in 21 ± 1% of the 
DNAs, within the telomere repeats 69 ± 1% (Figure 5.6D and insert), and at 
the junction of a t-loop 3 ± 4% of the time.  Aggregates of two or more DNAs 
bound by a large mass of TRF2 or TRF2∆B were observed, but not scored 
(data not shown).  Our results are therefore comparable with previous 
experiments in our laboratory that were optimized for t-loop formation, where 
TRF2 bound to t-loop junctions 19% of the time (69).  We show therefore that 
the basic domain of TRF2 is required for it to localize to model telomere ends 
and to facilitate t-loop formation in vitro.  
 
DISCUSSION 
In this study we used EM and gel-shift assays to evaluate the binding 
of several telomeric factors to an array of DNA templates.  We found that 
TRF2 was able to bind to the junctions of replication forks, chickenfoot 
structures and Holliday junctions, whereas TRF1 and the TRF2 truncation 
mutant, TRF2∆B, could not.  TRF2 binding to the DNA junctions did not 
depend on telomere sequences being present in the DNA, suggesting that the 
binding was not related to the telomere-specific Myb domain.  Also, a  
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Figure 5.6: Diminished t-loop formation and telomere ss/ds junction 
binding by TRF2∆B. 
(A, B C). Discrete complexes of TRF2 bound to the ends of the model 
telomeres (A) or at the strand invasion sites of the t-loop (B, C).  (D and 
insert). TRF2∆B typically bound within the TTAGGG repeat tract but not at the 
ends of the model telomere. Bar is equivalent to 450 bp in panels showing 
full-length molecules. 
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Figure 5.7: The basic domain of TRF2 promotes end-binding and t-loop 
formation on model telomeres in vitro. 
Binding of TRF2 and TRF2∆B to the large model telomeres was visualized by 
EM and quantified.  Percentages of molecules with protein bound at the DNA 
end (end-bound), bound within 560 bp from the end (within TTAGGG), bound 
at the t-loop invasion site (t-loops), or bound more than 560 bp from the DNA 
end (non-specific) were calculated as a fraction of all protein-bound molecules 
scored.  Data are represented as mean ± SD. 
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significant bias for 4-stranded junctions was observed, especially in non-
telomeric substrates, suggesting that these are a major target of TRF2 
structure-specific binding.   
Of particular interest were the different binding affinities of the two peptides 
used in this study.  The peptide encompassing the basic domain of TRF2 
bound well to DNA junctions, with a much higher affinity for 4-stranded 
chickenfoot structures than the 3-stranded replication fork templates.  In 
contrast, while the mutant peptide had the same net charge and amino acid 
composition of the TRF2 basic domain, binding to 4-stranded DNA junctions 
was almost completely disrupted.  Thus, the two amino acids which we 
rearranged in the mutant peptide and which are conserved within the TRF2 
basic domains of some mammals and birds, must be critical for TRF2 binding 
to 4-way DNA junctions.  Although the mutant peptide showed some DNA 
binding, this likely reflects an electrostatic interaction between the positively 
charged peptide and negatively charged DNA.  
The relatively small dissociation constants that were calculated for the 
proteins binding to radiolabeled Holliday junction probes reflected the strong, 
specific binding of TRF2 and the basic peptide, whereas TRF1, TRF2∆B, and 
the mutant peptide all had much higher dissociation constants, reflective of 
their weaker binding.  Also, when TRF2 binding to large model telomeres was 
examined by EM, we found that in the absence of the basic domain (TRF2∆B) 
the ability of TRF2 to target the end of the large model telomeres was 
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greatly diminished, as was its ability to facilitate t-loop formation. 
In gel-shift assays with a small telomeric probe, TRF1, TRF2 and 
TRF2∆B all shifted equally as well, with TRF2 and TRF2∆B having an almost 
identical affinity for the telomere probe.  Hence, deleting the basic domain 
from TRF2 does not appear to destabilize the Myb domain, which remained 
intact in the mutant.  The apparent Kd values also suggest that TRF2 DNA-
structure-binding via the basic domain is equally as strong as telomere-DNA-
binding via the Myb domain. 
The ability of TRF2 to bind telomeric DNA in a sequence-specific 
manner, but to have structure-dependent recruitment to the telomeric ds/ss 
junction as well as a possible function that is independent of its Myb-
dependent binding, is reminiscent of the multiple DNA-binding properties of 
p53.  p53 has a sequence-specific DNA binding domain as well as an 
additional domain at its extreme C terminus shown to bind in a sequence 
nonspecific manner to a wide variety of DNA targets (198,200,212).  These 
targets include unusual DNA structures such as the 4-stranded DNA Holliday 
junction, the Y-shaped replication fork, and chickenfoot intermediates of fork 
regression.  Intriguingly, this structure-specific binding domain of p53 is also 
characterized by basic residues, and it has the same length and overall 
positive charge as the TRF2 basic domain. 
Based on these findings we suggest a dual role for the TRF2 basic 
domain at the telomere.  The first role involves a role for TRF2 in t-loop 
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formation and stabilization.  We propose that the junction-binding property of 
the basic domain enhances the ability of TRF2, in conjunction with other 
telomere-associated proteins, to target chromosome ends and facilitate t-loop 
formation.  Junction binding capacity would also make it possible for TRF2 to 
contribute to the stability of the t-loop by binding to junctions formed at the 
strand invasion site of the t-loop.  The second role for TRF2 involving the 
basic domain would be a critical function during telomere replication in 
mammals, similar to that of Taz1 in the fission yeast (101).  We propose that if 
replication at the telomere stalls because of an impediment to the polymerase 
machinery, for instance a G-quartet in the unwound G-rich strand, TRF2 
would be able to recognize and bind to the chickenfoot intermediates 
produced by fork regression, thereby preventing the activity of Holliday 
junction resolvases.  TRF2 can then recruit factors like the RecQ helicases to 
unwind the chickenfoot structures, allowing replication to restart.  Indeed this 
may explain why TRF2 is able to interact with and stimulate the RecQ 
helicases, known to be important for proper telomere replication and 
maintenance in human cells  (105,134). 
Both of these proposed roles for TRF2 are consistent with the TRF2∆B 
phenotype previously observed, where deletion of the basic domain does not 
impede the DNA binding activity of TRF2 or its localization to telomeres in 
vivo, yet massive losses of telomeric DNA are seen, accompanied by the 
appearance of t-circles, a DNA damage response, and induction of 
senescence. Specifically, Wang et al. (2004) showed that cells 
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expressing the same level of TRF2∆B as control cells, but with impaired 
function of XRCC3 protein do not show telomere deletions.  We have shown 
in our laboratory that XRCC3 will bind to Holliday junctions as well as 
chickenfoot structures in vitro in complex with Rad51C (unpublished data).  
These observations suggest that without the basic domain, TRF2 is unable to 
protect complex DNA structures at the telomere, such as those that have 
been seen at model telomere replication forks or the junction structure at the 
t-loop, from being recognized and processed by DNA repair proteins, 
including XRCC3.  Nevertheless, because TRF2∆B is still able to suppress 
non-homologous end joining (NHEJ) events, we believe that the loss of 
junction binding ability does not directly lead to telomere uncapping, 
characterized by de-protection and loss of the 3′ overhang, as seen in cells 
expressing the dominant-negative allele of TRF2 (TRF2∆B∆M) (70).  
We previously observed that psoralen cross-linking stabilized t-loop 
formation in vitro on DNAs with very short overhangs, suggesting that more 
than just the nucleotides of the ss tail are inserted into the duplex to form the 
D-loop (69).  Based on our findings, we would further suggest that the more 
energetically favorable structure at the strand invasion site is a 4-way junction 
(preferred by TRF2 to the 3-way junction) formed by branch migration of the 
invasion site.  The data are also the first direct demonstration of TRF2 binding 
specifically and selectively to non-telomeric DNA in vitro, and may explain the 
ability of TRF2 to localize to sites of DNA damage in irradiated human 
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fibroblasts (208). 
CHAPTER 6: CONCLUSIONS AND FINAL THOUGHTS 
 
The primary goal of this study has been to examine some of the key 
components of the telomere by using electron microscopy and other 
biochemical techniques, in order to gain insight about the mechanisms in 
which they function.  In this regard, I believe that we have been 
overwhelmingly successful.   
Our examination of Euplotes aediculatus telomerase binding to 
telomeric DNA is the first visualization of telomerase from any source bound 
to a model telomere DNA.  We show that affinity-purified telomerase exists as 
a dimer in solution, that it binds to a model telomere as a homodimer and 
further that it has a strong propensity to bring together two model telomere 
DNAs in a complex which contains two DNAs, and at least four telomerase 
monomers.  The work will thus be of great interest to the field of telomeres 
and telomerase, as the possibility that telomerase binds to its substrate as a 
dimer has been proposed, but no direct data has been presented to support 
this model. 
In the study of replication fork regression in the two types of repetitive 
DNAs: the telomeric repeat TTAGGGn and the disease-associated triplet 
repeat (CTG)·(CAG)n, we describe a new feature of repetitive DNA that could 
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present a significant barrier to replication.  That is, the spontaneous and 
unassisted regression of model stalled replication forks consisting of repetitive 
sequences, to form stable chickenfoot structures that resemble recombination 
intermediates.  The work will be of great interest to two fields interested in 
repetitive DNA.  In the field of telomeres, little is known about replication of 
telomeric DNA.  Our data offer a possible explanation for the puzzling 
observation that helicases such as BLM and WRN are required for efficient 
replication through telomeres.  The data will also be of great interest to the 
field of triplet repeat diseases, where it supports a model for expansion of 
disease-related repeats that involves recombination-mediated replication 
restart. 
In our examination of TRF2 binding to DNA templates, we discovered 
that TRF2 has a high affinity for binding to DNA junctions, irrespective of the 
presence of telomeric repeats, and that this is facilitated by the basic domain 
of TRF2.  This work will be of great interest to the field of telomeres for 
several key reasons. TRF2 has been shown to be central to telomere 
protection and loss of its function leads to telomere fusions, apoptosis, and 
cell death.  Further, loss of the basic domain is also highly deleterious to the 
cell but why this is so has not been discovered in spite of many detailed 
studies by the de Lange laboratory and others.  We feel that the work 
presented in chapter 5 provides critical insights into this question and also 
opens the door for considering a panoply of additional functions for TRF2 in 
the cell.  Finally the data suggests a novel role for TRF2 at telomeric 
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replication forks, and it is the first direct demonstration of TRF2 binding 
selectively to non-telomeric DNA. 
When considering future directions of the work presented, several 
ideas come to mind.  In the study of Euplotes telomerase binding to model 
telomeric DNA, it would be interesting to determine whether the RNA 
component was involved in telomerase dimer formation.  Functional 
dimerization of the RNA component of human telomerase (hTR) has 
previously been shown to be dependent on the catalytically essential 
pseudoknot and CR4/CR5 domains (145,213,214).  Oligonucleotide probes 
that selectively base pair with conserved regions within the EaTR could thus 
be used to block potential RNA-RNA base pairing interactions, and 
complexes could then be visualized by EM to evaluate whether dimer 
formation has been disrupted. This oligonucleotide approach has been used 
previously to identify an RNA-RNA dimerization site in hTR, as well as to 
locate RNA recognition elements in HIV genomic RNA and tRNA (213,215-
217).  
Another experiment which we originally attempted, but which proved to 
be more difficult than expected, was the examination of E. aediculatus 
telomerase binding to the model telomeres under elongation conditions (i.e. in 
the presence of dTTP and dGTP).  This would still be an interesting 
experiment to do, however the conditions for binding would have to be 
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refined, to avoid obtaining the large aggregates of telomerase and DNA that 
were previously seen. 
In the study of replication fork regression in repetitive DNAs, only two 
types of repeats were studied, and only in one orientation each.  This study 
could therefore be expanded to include more of the disease-associated 
repeats as well as an examination of the orientation dependence (or lack 
thereof) of the spontaneous fork regression that was seen.  Furthermore, as 
previously discussed, a hallmark of the triplet repeats is the appearance of 
disease pathology when the repeat blocks expand beyond certain tight length 
thresholds (178).  We have proposed that the resolution of the chickenfoot 
intermediates of fork regression could lead to this expansion, possibly through 
the generation of extrachromosomal repeat DNA.  In support of this idea, ALT 
cells and some yeast mutants lacking telomerase are able to use 
recombination to generate very long telomeres, presumably through rolling 
circle replication of telomeric repeat-containing circles (51-53,55-57).  These 
t-circles are thought to originate from aberrant homologous recombination at 
the t-loop junction.  However, one cannot rule out that another source of these 
circles may be DNA cleaved out during aberrant recombination-mediated 
replication restart of stalled forks at the telomere.  Indeed, extrachromosomal 
linear telomeric DNA (that can easily be ligated to form t-circles) is found in 
ALT-associated PML bodies (APBs) (187).  Therefore, it would be interesting 
to determine whether repeat-containing DNA circles are also present in cells 
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cultured from individuals that have repeat-associated diseases. 
TRF2 and p53 have very similar characteristics in that they to bind 
DNA in a sequence-specific manner with one domain, and to DNA structures 
such as 4-stranded DNA Holliday junctions or chickenfoot structures with 
another domain (198,200,212).  In TRF2, the structure-specific binding is 
dependent on the N-terminal basic domain, whereas in p53, it is a C-terminal 
basic domain.  Interestingly, both of these domains are characterized by the 
same length and overall positive charge.  Circular dichroism spectroscopy has 
showed that both domains assume unordered structures in aqueous 
solutions, and the p53 basic domain has been shown to adopt a helical 
structure upon binding to its substrate (218) and data not shown).  Similar 
structural data of the conformation adopted by the TRF2 basic domain when 
bound to DNA has not been found, although it has a medium-to-high helical 
propensity when modeled on a helical wheel (data not shown).  Thus, it would 
be interesting to determine whether the p53 basic domain, when fused on to 
the N-terminus of the TRF2∆B protein (albeit with a sufficiently long linker 
region to allow for correct folding) could rescue the function of this mutant 
protein in the cell, thereby preventing aberrant t-loop HR, a DNA damage 
response, and senescence.   
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